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Abstract
Objective: To study different aspects of obesity during pregnancy, birth and the puerperium. 
Paper I is an intervention study of obese pregnant women. Paper II compares fatty acid (FA) 
patterns in breast milk and neonates´ plasma phospholipids in normal-weight mothers and an 
intervention group of obese mothers. Paper III reports the risk of obstetric anal sphincter la-
cerations in relation to maternal obesity among primiparas. Paper IV compares health care 
consumption and sick-listing among obese and normal-weight pregnant women. 
Methods: Paper I is a pilot clinical study of women with BMI ≥ 30, included during a first-tri-
mester prenatal visit. Twenty-five pregnant women were included in the intervention program, 
comprising visits to midwife, obstetrician and dietician, as well as weekly water gymnastics. 
Paper II is a randomized observational study of 41 obese and 41 normal-weight pregnant wo-
men. Twenty-nine obese women participating in a weight reduction program were included 
for comparison. FA were analyzed with capillary gas chromatography of lipids in breast milk 
collected at three and 10 days and one and two months postnatally, as well as in infants’ plasma 
sampled three days after birth. 
Paper III is a nationwide register-based study including 210,678 primiparas who gave vagi-
nal birth to a singleton, identified from the Swedish Medical Birth Register between Janua-
ry 1, 2003 and December 31, 2008. Body Mass Index (BMI) was categorized into four classes, 
according to World Health Organization (WHO) guidelines. 
Paper IV is a nationwide register-based study of 108,103 pregnant women, identified from the 
Swedish Medical Birth Register, the Maternal Health Care Register and the Swedish National 
Inpatient Register between January 1, 2003 and December 31, 2008. The women were catego-
rized into four BMI classes, according to WHO guidelines.
Results: Paper I: Fourteen (56 %) of the women had a gestational weight gain of ≤ 6 kg (study 
goal).  There were no cases of gestational diabetes. Three (12 %) women had mild hyperten-
sion. Three women (12 %) were delivered by emergency cesarean section. All babies were 
healthy and had normal birth weights. 
Paper II:  The concentrations of omega-3 FA were lower and the omega - 6 / omega - 3 ratio was 
higher in neonates and in consecutive samples of breast milk from obese mothers, compared 
to normal- weight mothers. FA patterns were more similar to those in normal-weight mothers 
when obese mothers participated in an intervention program with dietary advice and physical 
activity. 
Paper III:  In multivariate analyses, increasing BMI showed a nearly dose-response-type pro-
tective effect against grade III-IV sphincter lacerations.  
Paper IV: Obese women made more visits to midwives, doctors and the specialized an-tenatal 
care unit. They also complained of fear of childbirth more often. They had longer in-hospital 
stays and were sick-listed more often during pregnancy.
Conclusions: Obese pregnant women use more healthcare recourses during pregnancy. During 
delivery the risk for anal sphincter lacerations decreases with higher BMI. There might be an 
effect at eating and exercise habits with intervention and the results suggest the importance 
of health promoting guidance of obese pregnant women also influencing the early fatty acids 
pattern of their infants.
Keywords: Anal sphincter tears, Health care consumption, Obesity, Omega - 3, Omega - 6, 
Physical activity, Pregnancy, Weight reduction program.
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11. Introduction
Obesity has reached nearly epidemic proportions in the developed world. According 
to the World Health Organization (WHO), there are more than 300 million obese pe-
ople worldwide 1. Australia, Canada, the UK and the USA report obesity rates of 30 %, 
28 %, 30 % and 42 %, respectively, for individuals aged 30 years and up 2. Since 1980, 
people in Sweden have, on average, become 1 cm taller and 5 kg heavier. In 2011, more 
than 50 % of the men and about 40 % of the women in Sweden were overweight or obe-
se (obese women: 10.5 %; obese men: 11.8 %). The same year, 12.6 % of Swedish preg-
nant women were obese. The incidence of obesity has slowly rised since the early 90th 
(Figure 1) and the incidence of obesity differs in different parts of Sweden and women 
with a high level of education are less likely to be obese (Figure 2). Overweight and 
obesity in adulthood are linked to increased risk of mortality and morbidity. The Fra-
mingham Heart Study from Massachusetts, with follow-up from 1948 to 1990, showed 
that obese female smokers lost 7.2 years and obese male smokers lost 6.7 years of life 
expectancy, compared with normal-weight smokers 3. Both overweight and obesity are 
major causes of co-morbidities, which can lead to further morbidity and mortality. In 
a meta-analysis from 2009, Guh et al 4 provide a comprehensive review of the inci-
dence of co-morbidities related to obesity and overweight, presenting evidence of 18 
such co-morbidities. Obesity and overweight were associated with type II diabetes, all 
cancers except esophageal and prostate cancer, all cardiovascular diseases, asthma, 
gallbladder disease, osteoarthritis and chronic back pain. Obesity, defined by BMI, 
was most strongly associated with the incidence of type II diabetes in females (relative 
risk (RR): 12.41; 95 % confidence interval (CI): 9.03 - 17.06). The percentage of over-
weight and obese people has risen over the past 30 years; the increase is higher among 
men than women. In Sweden, significantly more children and young adults have be-
come overweight during the past 20 years, which will lead to health consequences for 
many years (Norberg & Danielsson, 2012) 5.
Figure 1. Body Mass Index (BMI) > 30 in early pregnancy, registered at antenatal 
clinic. Modified from Swedish Medical Birth Register, annual report 2013.
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21. 1. Obesity in pregnancy
Maternal obesity is a significant risk factor for adverse outcomes during pregnancy. In 
women, early onset of obesity is associated with menstrual irregularities, chronic oli-
go-/anovulation and infertility. These adverse effects of obesity are specifically evident 
in polycystic ovary syndrome (PCOS) 6. Women with a BMI of >35 are 26 - 49 % less 
likely to conceive, compared to those with a BMI of 21 - 29 7.
1. 1. 1. Miscarriage
A pooled analysis in a review from 2011 revealed a higher miscarriage rate (13.6 %) 
in 3 800 obese women than the corresponding rate (10.7 %) in 17 146 normal-weight 
women (odds ratio (OR) 1.31; 95 % CI: 1.18 - 1.46). They also found a higher preva-
lence of recurrent early miscarriage in obese than in normal-weight women (0.4 % ver-
sus 0.1 %; OR: 3.51; 95 % CI: 1.03 - 12.01) 8. The exact reason for this obesity-related 
increased risk of miscarriage is unknown, but the higher rates of PCOS and insulin 
resistance among obese women 9 have been discussed as part of the explanation. 
1. 1. 2. Congenital malformations
Paternal pre-pregnancy obesity is associated with congenital malformations, particu-
larly anomalies of the central nervous system and heart 10-12. Maternal obesity is as-
sociated with a 1.7 - fold increased risk of neural tube defects, and severe obesity is 
associated with a risk increased more than 3 - fold 13. The biological mechanisms be-
hind this association between maternal obesity and birth defects are unknown. Altered 
glucose metabolism and poor maternal diet are potential explanations. Lower maternal 
folate levels, well-known to be implicated in the etiology of neural tube defects, may 
be a factor. Hyperinsulinemia is strongly associated with neural tube defects and may 
represent the physiological pathway responsible for the increased risk of this particular 
malformation in both the diabetic and obese populations 14. 
Figure 2. Modified from Swedish Medical Birth Register, annual report 2013
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31. 1. 3. Stillbirth and neonatal death
Stillbirth remains a serious reproductive complication, with a frequency of 2 - 5 per 
1 000 births, and constitutes more than half of all perinatal deaths 15.
Women with pre-pregnancy obesity have more than twice the risk of stillbirth and 
neonatal death 16-18, compared to normal-weight women 19. A meta-analysis by Flena-
dy et al 20 showed that maternal overweight and obesity was the highest-ranking mo-
difiable risk factor for antenatal death, contributing to around 8 000 stillbirths (≥ 22 
weeks’ gestation) annually, across all high-income countries. The pregnancy disorders 
associated with the highest risk of stillbirth were small for gestational age (SGA) and 
placental abruption, which highlights the role of placental pathology in stillbirth. 
The mechanism underlying the increased risk of stillbirth associated with higher BMI 
is a matter of speculation. It has been suggested that infants are often discretely SGA in 
unexplained stillbirths 21. Kristensen et al found that the birth weights of babies born, 
at term or post-term, to obese women were lower among the stillborn, compared with 
live-born neonates 17.
Gestational diabetes, preeclampsia and eclampsia are more common among over-
weight and obese women, but even after these groups are excluded from studies, the 
increased stillbirth risk remains. Obesity is known to be associated with disturbances in 
lipid metabolism. Hyperlipidemia may, directly or indirectly through lipid peroxidases, 
damage endothelial cells and promote vasoconstriction and platelet aggregation, which 
may in turn contribute to the preeclampsia process 22. The risk might increase with 
hyperlipidemia and insulin resistance, in cases of which fibrinolytic activity is known 
to be markedly decreased 23. This has been suggested to increase the risk of placental 
thrombosis and decrease placental perfusion 17.
1. 1. 4. Gestational diabetes
Since obesity prediposes to type II diabetes, obese pregnant women’s risk of gestational 
diabetes increases with rising BMI. The OR increased from 3.56 [95 % CI: 3.05 - 4.21] 
in obese women to 8.56 [95 % CI: 5.07 - 16.04] in severely obese women, compared to 
normal-weight controls, in a meta-analysis by Chu et al 24. 
1. 1. 5. Preeclampsia and gestational hypertension 
Preeclampsia is a hypertensive disorder of pregnancy, defined as hypertension (blood 
pressure ≥ 140 / 90 mmHg) and proteinuria (urinary protein ≥ 300 mg / 24 h). It occurs 
in 5 - 7 % of all pregnancies and is a leading cause of maternal and fetal morbidity and 
mortality 25. Elevated pre-pregnancy BMI is a strong independent risk factor for pre-
eclampsia and the degree of obesity is related to the severity of preeclampsia. A study 
by Bodnar et al 26 showed that the ORs for preeclampsia were 1.7 for overweight white 
women, 3.4 for obese white women, 2.1 for overweight black women and 3.2 for obese 
black women. The ORs for severe hypertension of pregnancy in white women with 
BMI 25 and 30 were 3.6 and 8.8, respectively, while the corresponding respective figu-
res in black women were 3.0 and 4.9. Both weight gain during adulthood and weight 
gain between pregnancies increase the risk of preeclampsia. Suggested explanations 
for this higher risk in obese women are systemic inflammation, hyperlipidemia, oxida-
tive stress, insulin resistance, endothelial dysfunction, reduced immune function and 
lifestyle factors such as poor antenatal diet and antenatal physical inactivity 22,27.
41. 1. 6. Preterm delivery
A recent study in the Journal of the American Medical Association showed that preterm 
deliveries increased with elevated BMI and that the overweight- and obesity-related 
risks were the highest for extremely preterm delivery. Among normal-weight women, 
the rate of extremely preterm delivery was 0.17 %, while the rate for obese women was 
0.27 %. The association between high BMI and the risk of moderately preterm delivery 
was stronger in short women than in taller women. The risk of medically indicated 
preterm delivery also increased with higher BMI. Maternal obesity is associated with 
inflammatory up-regulation through increased production of adipokines in adipose 
tissue and enhanced systemic secretion of pro-inflammatory cytokines 28. In sponta-
neous preterm delivery, there are elevated levels of inflammatory proteins (cytokines), 
which are associated with cervical ripening and may also cause both weakening of the 
membranes and preterm myometrial contractions. Additional mechanisms that may 
contribute to preterm delivery in obese women include endothelial dysfunction, insu-
lin resistance, oxidative stress, and lipotoxicity 28. Obese women have also increased 
risks of genital 29 and urinary tract 30 infections, which are recognized risk factors for 
chorioamnionitis and preterm delivery 31. 
1. 1. 7. Small for gestational age and macrosomia
A study by Beaten et al showed that obese, overweight, and normal-weight women 
were each slightly less likely to deliver a SGA (< 10th percentile) baby as well as each 
more likely to deliver a macrosomic infant (≥ 4,000 g) 32. Other studies have shown 
that obesity is an independent risk factor for SGA (OR 1.24). Maternal age ≥ 35 years 
(OR 1.16), nulliparity (OR 1.13), cigarette smoking (OR 2.01), gestational hyperten-
sion (1.46), preeclampsia (OR 2.94), chronic hypertension (OR 1.68) and placental 
abruption (OR 2.57) are other risk factors. Gestational diabetes (OR 0.80) and type I 
diabetes (OR 0.26) are, on the other hand, associated with reduced risk 33,34. Women 
with a prior history of bariatric surgery, regardless of obesity status, were more likely 
to have anemia, chronic hypertension, endocrine disorders and SGA infants 35. 
There are associations between paternal obesity and birth weight as well. In the SCOPE 
study in Australia, men who fathered an SGA infant were more likely to be obese (OR 
1.50) and to have central adiposity (OR 1.53), compared with men who fathered a 
non-SGA infant. Elevated paternal blood pressure was, however, not associated with 
SGA  36,34.
1. 1. 8. Venous thromboembolism
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmo-
nary embolism (PE), occurs at a rate of more than 1 per 1 000 adults in western coun-
tries. The majority of cases occur in those aged over 45 years 37. A systematic literature 
review by Ageno et al 38 found that obesity (BMI > 30) more than doubled the risk of 
VTE (OR 2.33; 95 % CI: 1.68 - 2.34). Pregnant women are 4 - 5 times more likely to 
develop VTE than non-pregnant women 39. VTE remains one of the most common 
causes of maternal mortality in the developed world 40. The risk of DVT is 1.36 per 
1,000 deliveries and the risk of pulmonary embolism (PE) is 0.36 per 1 000 deliveries. 
Half of pregnancy-related VTE occurs postpartum 41. James et al found that obesity 
significantly increased the risk of VTE during pregnancy (OR 4.4; 95 % CI: 3.4-5.7) 41. 
A normal pregnancy is accompanied by changes in the coagulation and fibrinolytic 
systems. Levels of clotting Factors I, II, VII, VIII, IX and XII increase, while protein 
S levels decline and fibrinolysis is inhibited. There is also a significant decrease in the 
activity of activated protein C, an important anticoagulant, as gestation progresses. 
5These physiological changes may be important for minimizing intrapartum blood loss 
but they entail an increased risk of VTE during pregnancy and the postpartum period 42.
There are several possible explanations for obese individuals’ higher risk of VTE. More 
body fat, especially abdominal fat, might limit venous return; obesity is associated with 
chronically elevated intra-abdominal pressure and decreased blood velocity in the fe-
moral vein. Furthermore, there may be increased inflammation, oxidative stress, and 
endothelial dysfunction 43. Visceral adipose tissue is metabolically active, producing 
adipokines such as leptin, important in the regulation of body weight. Leptin levels are 
elevated in obese individuals since the central nervous system appears to gradually be-
come resistant to its effects. Leptin is associated with adenosine diphosphate-induced 
platelet aggregation 44 and correlated with tissue plasminogen activator (tPA) antigen. 
Higher concentrations of plasminogen activator inhibitor-1 (PAI-1) inhibit fibrinolysis, 
thereby maintaining a thrombotic state.
BMI has also been shown to positively correlate with Factor VII, Factor VIIIc, fibrino-
gen and von Willebrand Factor levels. The chronic inflammation of obesity or hyperin-
sulinemia may be responsible for these observed elevations 45. Factor VIII concentra-
tions are strongly associated with increased risk of VTE, as is hyperfibrinogenemia 46.
There are also several lifestyle factors that might influence the relationship between 
obesity and VTE. Epidemiological evidence is inconclusive about the effects of physi-
cal activity (PA) in overweight and obese people. A 2009 study from Sweden showed 
that non-smoking women who were physically active and consumed alcohol in mo-
deration were at lower risk of VTE 47. The LITE study showed that a diet with more 
plant foods and fish and less meat and processed meat reduced the incidence of VTE 
in middle-aged women 48.
1. 1. 9. Labor
Monitoring labor progress may be more difficult in obese women due to the greater 
depth required for ultrasound penetration to the level of the fetus and increased difficul-
ty in tracing contractions. Obesity significantly increases the incidence of cesarean de-
livery. In a study of nulliparas, Weiss et al 49 found a cesarean delivery rate of 20.7 % in 
the control group, compared with 33.8 % in the obese group and 47.4 % in the morbidly 
obese group. In a study 
by Baeten et al 31, the 
cesarean delivery rate 
was nearly doubled in 
women with BMI > 
30. Obesity is associ-
ated with an increase 
in operative complica-
tions such as excessive 
blood loss, increased 
duration of surgery and 
increased incidence of 
post-operative wound 
infection and endome-
tritis 49,50.
General anesthesia for 
cesarean delivery is as-
sociated with a much 
 
Figure 3. Labor curve for nulliparous women stratified by 
body mass index (BMI) Norman. Effect on Obesity on the la-
bor Curve. Obstet. and Gynecol. 2012
6higher risk of maternal mortality, compared with regional anesthesia 51. Obesity was 
found to be a major risk factor for maternal mortality in several studies 51,52, with failed 
intubation and aspiration representing the cause of death in the majority of cases. The 
incidence of failed intubation in the morbidly obese parturient has been reported to be 
as high as 33 %. The duration of the first stage of labor among both nulliparous and 
multiparous women with BMI ≥ 30 is longer and cervical dilation is slower (4.7 vs. 4.1 
hours, from 4 to 10 cm). The difference in the progression of dilation from 4 cm to 6 
cm was the most pronounced (2.2 vs. 1.9 hours) 53. The difference in labor progress is 
related exclusively to the latent phase and is thus not related the active phase of labor. 
Fyfe et al found that obese women who reached the second stage of labor had a higher 
rate of spontaneous vaginal birth and fewer operative vaginal births, compared with 
women with normal BMI 54. In our study from 2013, we found that increasing BMI had 
a nearly dose-response-type protective effect against grade III and IV perineal tears, in 
comparison with normal-weight women 55.
It is important to monitor the second stage of labor carefully when the parturient is obe-
se, since the risks of low Apgar score, meconium aspiration and shoulder dystocia are 
increased. In a study from 2004, Cedergren et al showed that morbidly obese patients 
(BMI > 40) had a 3-fold increase in shoulder dystocia and close to a 3-fold increased 
risk of meconium aspiration and fetal distress. The associations were similar, but less 
strong, for women with BMI between 35.1 and 40. Interestingly, the incidence of pla-
centa previa decreased among obese and morbidly obese women 56.
1. 1. 10. The pelvic floor and risk factors for perineal tears
The pelvic organs are suspended by the pelvic ligaments and supported by the levator 
ani muscles, which play a critical role in supporting the pelvic visceral organs and a 
major role in urinary, defecatory and sexual function. The levator ani muscle has a th-
ree-dimensional structure; its anterior portion (pubococcygeal and puborectal) is orien-
ted vertically as a sling around the mid-urethra, vagina, and ano-rectum (Figure 4). The 
opening in the levator ani muscle through which the urethra and vagina pass is called 
the urogenital hiatus, limited ventrally by the pubic bones, laterally by the levator ani 
muscles, and dorsally by the perineal body and the external anal sphincter 57. The pos-
terior portion of the levator ani, the iliococcygeal muscle, has a horizontal upwardly 
biconvex shape; it serves as a supportive diaphragm while the anterior portion closes 
the urogenital hiatus, pulling the urethra, vagina, perineum, and ano-rectum toward the 
pubic bone. When the fetus emerges through the birth canal, the widest part of the fetal 
head stretches the pelvic floor muscles, fascia and nerves and may cause reversible 
or permanent damage by direct laceration 
or ischemia 58. Pudendal nerve denervation, 
which occurs primarily during the second 
stage of labor, has been demonstrated in 
80 % of women following their first vagi-
nal delivery. Pelvic floor denervation has 
been implicated in the etiology of urinary 
incontinence, pelvic organ prolapse, chro-
nic constipation and defecatory difficulty. 
Stretching and disruption of the pelvic floor 
muscles, as well as fascial tears, can heal 
but the resulting connective tissue may not 
be of the same tensile strength as the origi-
nal 59 
Figure 4. The levator ani muscles of the 
female pelvic floor a) Ileocyccygeus, b) 
Pubococcygeus, c) Puborectalis
71. 1. 11. Perineal tears
Ruptures of the pelvic floor during childbirth are divided into four categories, based on 
morphological severity according to the International Classification of Diseases (ICD) 
10th revision:
Grade I: a tear in the vaginal mucosa or superficial perineal skin but not in the  un-
derlying tissue
Grade II: a tear extending beyond the perineal skin and vaginal mucosa to perinal 
muscles and fascia
Grade III: a tear involving the muscles of the anal sphincter complex 
Grade IV:  a complete rupture of the anal sphincter muscles, including the anal or 
rectal mucosa
Risk factors for grade III-IV ruptures of the pelvic floor are: nulliparity, fundal press-
ure, midline episiotomy, birth weight > 4.5 kg, instrumental delivery, perineal edema, 
poor ocular surveillance of the perineum, deficient perineal protection during delivery 
and protracted final phase of the second stage 60,61. The reasons for the above-mentio-
ned, intriguing protective effect of increasing BMI against severe perineal tears are as 
yet unclear.
1. 2. Nutrition during pregnancy and breastfeeding 
1. 2. 1. The Barker hypothesis
Nutrition plays a key role in many aspects of health. Excessive caloric intake is a major 
determinant of complex chronic diseases, such as obesity, type II diabetes, cardiovas-
cular disease and even cancer. In poor countries, malnutrition and under-nutrition, es-
pecially during the perinatal period, increase not only neonatal mortality and perinatal 
morbidities but also the risk of chronic disease during adulthood 62. There is extensi-
ve epidemiologic and experimental data showing that early sub-optimal nutrition can 
have health consequences several decades later. This association has been conceptuali-
zed into the Developmental Origins of Health and Disease Hypothesis, first described 
by David Barker 63,64. 
Epigenetics is defined as the study of heritable changes in gene expression that do not 
involve alterations in the DNA sequence 65. Epigenetic marks include DNA methyla-
tion, histone modifications and a variety of non-coding RNAs 66. The gene expressions 
are plastic and seem to respond to different environmental signals, including diet.
1. 2. 2. Obesity among children
Also among children, overweight and obesity are a rising problem in the Western world. 
Decreased PA and more junk food intake are contributing factors. A study by Whitaker 
et al showed that children from low-income families with obese mothers had a more 
than doubled risk of obesity at two to four years of age 67. Other risk factors are high 
weight gain between birth and 5 months, maternal smoking during pregnancy, parental 
overweight or obesity, decreasing duration of breastfeeding and earlier introduction of 
complementary food 68,69.
81. 2. 3. Nutrition during pregnancy 
The supply of substrates to the developing fetus and placenta is essential for normal 
growth and development. Availability of nutrients for the fetus is dependent on mater-
nal nutritional status and maternal diet.
During pregnancy, plasma volume expands, which affects absorption. Urinary excre-
tion and metabolism of different nutrients change nutrient levels and availability. Pla-
cental size, function and metabolism determine the extent of nutrient transfer to the 
fetus and how it utilizes available substrates, which in turn influences its growth and 
endocrine status 70-72.
In developing countries, low pre-pregnancy weight and low caloric intake or weight 
gain during pregnancy are major contributors to the incidence of intrauterine growth 
retardation (IUGR) 73. Poor nutrition is also common under deprived socio-economic 
conditions in developed countries. On the other hand, pregnant women with eating 
disorders in high-income countries risk adverse neonatal outcomes associated with 
IUGR and microcephaly 74. Fetal nutrition during critical periods of development can 
thus have specific effects on fetal structure and function, contributing to an increased 
susceptibility to adult disease 63. 
Epidemiological studies of the Dutch famine, in 1944-1945 at the end of the Second 
World War, revealed that the timing of malnutrition is important for subsequent health 
outcome. For months during the winter between 1944 and 1945, people in the Ger-
man-occupied part of the Netherlands were only given two pieces of bread, two potato-
es and a piece of sugar beet per day. Exclusive exposure to this diet with extremely low 
fat content, during the last trimester of pregnancy and the first months of life, resulted 
in a decreased rate of obesity during adult life, whereas exposure to the famine during 
the first half of fetal life was associated with an increased rate of obesity 75. In another 
study, famine exposure during the third trimester of pregnancy reduced birth weight 
by around 10 % but early pregnancy, mid-pregnancy or periconceptional exposure did 
not affect birth weight in one cohort 76. Recent studies provide evidence that everyday 
maternal dietary composition during pregnancy can influence birth size in developed 
countries. A study by Moore et.al in Australia showed that the proportion of energy de-
rived from protein in early pregnancy was positively associated with birth weight and 
placental weight. They also found that the baby’s ponderal index was negatively rela-
ted with the proportion of energy from carbohydrates in early and late pregnancy. The 
association was independent of the mothers’ BMI and weight gain during pregnancy 77. 
Godfrey et al 78 obtained similar findings, while no effect of maternal nutrition on birth 
size was observed in a study by Mathews et al 79.
Maternal obesity is due, at least in part, to poor dietary habits 80. Micronutrients are 
essential for cell processes, including protein translation, enzymatic reactions and gene 
expression regulation. Animal studies demonstrate teratogenic effects of deficiencies 
in micronutrients such as folate or zinc 81. In humans, inadequate folic acid intake in-
creases the risk of neural tube defects while periconceptional folate supplementation 
has a strong protective effect 82. A study from India showed that adequate maternal 
folate status, accompanied by low maternal vitamin B12, predicts increased risk of in-
sulin resistance in children 83. This also provides evidence that maternal micronutrient 
balance can influence the offspring’s health.
The knowledge of energy requirements during pregnancy, which differ among indivi-
dual women, is incomplete. The 2004 WHO recommendations suggest that the respec-
tive daily energy requirements are 0.35 MJ in the first trimester, 1.2 MJ in the second 
trimester and 2.0 MJ in the third trimester. 
91. 2. 4. Especially important nutrients during pregnancy
1. 2. 4. 1. Iodine 
The fetal thyroid gland does not become active until after the first trimester, prior to 
which the fetus is totally dependent on a maternal source of thyroid hormones, espe-
cially for normal brain development. An adequate dietary intake of iodine is essential 
during pregnancy in order to maintain maternal thyroid function, and later in pregnan-
cy for fetal thyroid function 84. The iodine requirement is increased during pregnancy, 
both in order to provide for the fetus’s needs and to compensate for the increased renal 
clearance of iodine 85. Inadequate maternal iodine intake can lead to neurodevelopme-
ntal delays, neurological abnormalities and impaired cognitive and motor development 
in the child 86 Iodine deficiency is likely to be the most common preventable cause of 
mental retardation and brain damage in the world. “Endemic cretinism”, a grave and 
irreversible form of mental retardation, is closely identified with iodine deficiency. A 
study by Vermiglio et al found associations between iodine deficiency in mothers and 
increased risk of attention deficit and hyperactivity disorder (ADHD) in their child-
ren 87. Iodine deficiency has also been associated with spontaneous abortion, stillbirth, 
low birth weight, high neonatal mortality and delayed growth 88,89. According to the 
2004 Nordic Nutrition Recommendations (NNR), the daily iodine requirement is 175 
μg during pregnancy and 200 μg during lactation 90
1. 2. 4. 2. Iron
The iron requirement is increased during pregnancy in order to meet the needs of the 
developing fetus, as well as the need for additional maternal tissue. Iron plays an im-
portant role in the body, both in transporting oxygen from the lungs to the tissues via 
hemoglobin (Hb), and related to the oxygen-binding function of myoglobin in muscle 
tissue. Iron homeostasis is tightly controlled and regulated by intestinal absorption of 
dietary iron, which increases when iron stores are low 91. There are two types of iron in 
the diet: heme iron, mostly found in meat, and non-heme iron, found in plant-derived 
food products such as grains and vegetables 92. Fourteen percent of the iron in a typical 
Swedish diet is absorbed 92.
No relationship between maternal and cord serum ferritin (sFt) has been observed, but 
infants born to women with anemia or with iron deficiency without anemia have been 
shown to have lower iron stores 93,94. A maternal sFt < 12 ug/L at delivery has been 
proposed as a threshold, below which fetal iron stores are at risk of being deficient. 
Haider et al showed that an improvement in prenatal mean Hb concentration linearly 
increased birth weight 95.
A considerable proportion of pregnant women develop iron deficiency and anemia 
during pregnancy 96. A study from Denmark showed that 10 % of Danish women had 
iron deficiency and 2 - 4% had anemia. Only 18 % had iron stores of at least 500 mg 
(sFt > 70 ug/L), the estimated level to cover the net iron requirement of a pregnan-
cy  97. The current Swedish recommendation is early sFt screening (before week 15). 
Iron supplementation should either start immediately (if sFt < 20 ug / L) or in week 20 
(if sFt 20 - 60 ug/L), and women with an initial sFt > 60 ug / L should not take iron supp-
lements. 
1. 2. 4. 3. Calcium
It has been frequently reported that women of childbearing age do not consume the 
dietary reference intake of calcium. Fetal calcium deposition has been shown to peak at 
350 mg / day in the third trimester, and maternal calcium absorption increases to meet 
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that demand, with greater increases in absorption reported among women with low 
intakes 98. Maternal calcium absorption increases significantly during the second and 
third trimesters, as does maternal bone turnover 99,100. 
Low calcium intake during pregnancy may stimulate parathyroid hormone (PTH) se-
cretion, increasing intracellular calcium and smooth muscle contractibility, and/or re-
leasing renin from the kidney, leading to vasoconstriction and retention of sodium and 
fluid. These physiological changes can lead to the development of pregnancy-induced 
hypertension and preeclampsia 101. A Cochrane report from 2010 concluded that the 
average risk of preeclampsia was reduced in women taking calcium supplements (RR 
0.45) and that the effect was greatest in women with low baseline calcium intakes (RR 
0.36). They found that calcium supplements reduced the rare occurrence of the com-
posite outcome ‘death or serious morbidity’ in women 102. However, the same review 
reported no overall association between calcium intake and the risk of preterm birth or 
stillbirth 102.
It has been reported that parity influences bone loss during gestation, with greater los-
ses reported in primiparas than in multiparas 103. The number of childbirths does not 
appear to increase later fracture risk in women, with studies showing either a nega-
tive 104,105 or a neutral 106 relationship between parity and the risk of fracture. Women 
who begin pregnancy with adequate intake of at least 1 000 mg of calcium/day may 
not need additional calcium, but women with suboptimal intake (<500 mg) may need 
additional amounts of calcium to meet both maternal and fetal bone requirements.
1. 2. 4. 4. Vitamin D
Vitamin D is a fat-soluble vitamin, crucial for skeletal development. It is predomi-
nantly found in foods of animal origin (fatty fish, to some extent in eggs and meat) 
and fortified products (milk with ≤ 1.5 % fat and margarine in Sweden). However, the 
primary source of vitamin D is synthesis in the skin following exposure to ultraviolet 
light, where 7-dehydroxycholesterol is converted to pre-vitamin D3. The NNR defi-
ne a vitamin D level, measured as serum / plasma concentration of 25 - (OH) D3, of 
50 nmol / L as adequate. The recommended daily intake during pregnancy and lactation 
is10 μg (400 IU). With limited sun exposure, the current recommended intake may be 
inadequate to maintain optimal circulating 25 - (OH) D3 concentrations and to maintain 
health, especially in pregnant 107 and lactating women 108.
During pregnancy and lactation, the vitamin D requirement is elevated due to a need 
for enhanced maternal absorption of calcium in order to supply fetal and neonatal bo-
nes 109. There are considerable changes in maternal vitamin D and calcium metabolism, 
to ensure the calcium required for fetal bone mineral accretion 110. An active metabolite 
of vitamin D, 1,25(OH) 2D, increases the efficiency of intestinal calcium absorption, 
decreases renal calcium excretion and, in conjunction with PTH, mobilizes calcium 
from bone 110. Vitamin D is also important for fetal growth, nervous system develop-
ment, lung maturation and fetal immune system function 111. Vitamin D insufficiency 
during infancy can result in defective mineralization with the development of rick-
ets in children 110. Maternal vitamin D deficiency might also contribute to low birth 
weight 112, impaired fetal growth 110 and impaired fetal bone ossification 113.Vitamin 
D-deficient pregnant women can develop secondary hyperparathyroidism, which leads 
to transitory hypoparathyroidism and hypocalcemia in neonates 114.
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1. 2. 4. 5. Essential fatty acids in breast milk and during pregnancy
The omega-3 (n-3) fatty acid alpha-linoleic acid (ALA) and the omega-6 (n-6) FA 
linoleic acid (18:2n-6, LA) are essential fatty acids (EFAs), as they cannot be produ-
ced by the human body. The EFAs are converted into long-chain polyunsaturated fatty 
acids (LCPUFA); n-6 fatty acid LA to arachidonic acid (20:4n-6, ARA). The n-3 fatty 
acid ALA is converted to eicosapentaenoic acid (20:5n-3, EPA) and docosahexaenoic 
acid (22:6n-3, DHA). Conversion from ALA and LA to EPA, DHA and AA is low, 
1-10 % 115,116. Conversion rates are lower in infants (especially premature infants). Sin-
ce the conversion rate is low, especially of EPA and DHA, there has been discussion 
concerning whether they are essential in the diet, as are ALA and LA, especially in 
early life. There are also indications that the balance between n-6 and n-3 fatty acids 
is important, since there is a metabolic transformation competition between LA and 
ALA for the same enzymes, both regarding desaturation and elongation to their longer 
derivates 117. 
Transfer through the placenta of DHA is an active transport mechanism, resulting in 
a decrease in maternal DHA, if not compensated for in the diet during pregnancy and 
breastfeeding 118. The optimal intake is not known, but it has been suggested that the 
newborn infant needs about 35 mg DHA and 50 - 60 mg AA daily 119. 
Concentrations of LA, ALA, DHA and EPA in breast milk depend on the mother’s diet 
and fat stores 120. The reported mean DHA and AA levels in human milk worldwide 
are 0.32 % and 0.47 %, respectively, of the total fatty acids. Iron, zinc, vitamin B6 and 
vitamin E are required for the conversion of ALA and LA to EPA, DHA and AA, due 
to their functions in elongation enzymes 121. It has also been shown in a rat model that 
folic acid intake influences brain DHA levels in adult offspring 122.
LA and ALA and their long-chain derivatives EPA, DHA and AA are important for 
numerous physiological and developmental requirements in humans. The brain is com-
posed of large amounts of both DHA and AA. During the third trimester of pregnancy 
and the first year of life, it grows rapidly and an adequate supply of these FA is thought 
to be essential for optimal development 123,124. DHA is also a major component of the 
retina and thus affects visual acuity 124. AA and DHA are vital structural elements of 
cell membranes. LCPUFAs affect growth through their role in the synthesis of pros-
taglandins and growth hormones and the biosynthesis of membrane components 125,124. 
In a cohort study of premature infants, 98 % of the mothers had n-3 FA intakes below 
recommended levels and a relatively high n-6 FA intake; a negative correlation was 
found between n-6/n-3 FA ratios and early development up to 18 months of corrected 
age 126. Another study showed that the AA / DHA ratio was important for normal motor 
development in term-born infants at three months of age 127. A study by Donahue et 
al found an association between an early high n-6/n-3 FA ratio and obesity in 3-year-
olds 128.
Other possible benefits of n-3 FA during pregnancy have been suggested. A prospective 
study in India showed that women with preeclampsia had reduced total n-3 FA levels 
(p < 0.05), increased n-6/n-3 ratios (p < 0.05), higher oxidative stress (p < 0.05) and 
lower antioxidant (p < 0.05) levels. Similar trends were also observed in cord samples 
after delivery 129. Observational studies in both developed and developing countries 
indicate a likely association between low DHA levels (measured in breast milk) and 
postpartum depression 130. 
Modern diets often provide high amounts of LA and are relatively low in ALA 131. Fish, 
in contrast with domesticated animals, are rich in EPA and DHA, due to the synthesis 
of EPA and DHA in phytoplankton and their transfer up the aquatic food chain. In 
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the Stone Age, the n-6/n-3 ratio in hu-
mans was close to 1 132. The ratio to-
day varies widely, from less than 5 in 
Japan to more than 30 in the USA. In 
most European countries, the n-6/n-3 
ratio is between 8 and 20 133. One re-
ason for reduced intake of seafood 
could be fear of methyl mercury and 
dioxin pollution in fish, leading au-
thorities to recommend a reduction, 
especially in pregnant women. Over-
fishing with increased prices, and less 
access to marine food in populations 
that depend on fishing, are other pro-
blems. The increase of fast food and 
processed food, often made with oils 
rich in n-6 FA, makes the n-6/n-3 ratio 
even higher. 
Most of our knowledge of the possible 
importance of LCPUFA for long-term 
development is obtained from animal 
studies. Rodents with EFA deficiency 
during fetal life have reduced growth 
as neonates and develop obesity and 
low bone mineral density in adult 
life 134. High fasting insulin in the 
adult offspring was found when dams 
received a diet with a high n-6/n-3 ra-
tio 135. Animal studies have also found 
that an increase in fat mass caused 
by high insulin can be balanced by 
an increase in DHA 136. A study by 
Palsdottir et al showed that lactating 
dams that only received saturated fat, 
resulting in very low levels of EFA 
and LCPUFA in breast milk, were re-
sistant to obesity when given a high-
fat diet as adults. This was associated 
with changes in the mRNA expres-
sion of uncoupling protein 1 in brown 
fat tissue and in transcription factors 
in the liver. The results indicate that 
the FA composition during lactation is 
important for body composition and glucose tolerance in the adult offspring 137. It is 
known that fat stores are formed during the latter part of the third trimester in humans, 
and during the second postnatal week in rodents 138. There might thus be indications 
that the FA pattern during the perinatal period may have long-term effects. A study 
from Argentina showed that obese mothers had lower n-6/n-3 ratios in their breast milk 
than normal-weight mothers 139.
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Figure 5. Metabolic conversion of the essential 
fatty acids, LA (omega-6 series) and ALA (ome-
ga-3 series) to long-chain LCPUFA
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1. 3. Human breast milk
Human breast milk is considered to be the best nutrition for the newborn infant because 
it contains optimal ingredients for healthy growth and development and it is recom-
mended as the exclusive food for the infant from birth to six months of age (WHO, 
2002). Breastfeeding protects against gastrointestinal infections, respiratory infections 
140 and allergies 141. Breastfeeding has also been associated with a reduced long-term 
risk of diseases such as inflammatory bowel disease, obesity and diabetes 142.
Colostrum is usually present for the first three to five days after birth, followed by 
transitional milk until about two to three weeks postpartum, after which breast milk is 
considered to be mature. Breast milk contains high concentrations of factors providing 
immunological support and protection, such as immunoglobulin, lactoferrin, oligosac-
charides and active viable immune cells. It also contains cell proliferation-inducing 
factors thought to promote development of the neonate’s gastrointestinal tract and to 
stimulate hematopoiesis and maturation of the immune system 143,144.
1. 3. 1. Proteins in breast milk
The protein content in human breast milk is very low and is not affected by maternal 
diet; it increases with higher maternal body weight and nursing frequency and decrea-
ses in mothers producing higher amounts of milk 145. The proteins are divided into the 
whey and casein fractions or complexes, each comprising a remarkable array of spe-
cific proteins and peptides 146. The most abundant proteins are casein, a-lactalbumin, 
lactoferrin, secretory IgA, lysozyme and albumin 147. Non-protein nitrogen-containing 
Figure 6. The mean protein content of full-term donor and preterm milk and full-term 
fore- and hindmilk during the first 6 month of lactation. Vertical lines show standard 
errors of means. (From Saarela, 2005)
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compounds, including urea, uric acid, creatine, creatinine, amino acids and nucleoti-
des, comprise approximately 25 % of breast milk nitrogen. Compared to bovine milk, 
human milk contains only one third of the protein (Frank, 1988). Neither lactose nor 
protein concentrations vary throughout one breastfeeding 148. Colostrum, however, has 
a higher protein content (30 - 70 g / L or 3 - 7 %) than mature breast milk (7 - 25 g / L or 
0.7 - 2.5 %), which may additionally benefit the infant during the first few days after 
birth 149,148. The protein content of human breast milk decreases rapidly during the first 
month and then decreases slowly until six months of lactation. It is well known that the 
total protein concentration is higher in preterm than full-term milk in the early postpar-
tum period 150. It has also been found that the protein composition changes rapidly and 
more markedly in preterm than in full-term milk, so that immunological components 
(e.g. IgA) decrease and nutritional components, such as lactalbumin, increase 151.
1. 3. 2. Fat in breast milk
Of the major digestible energy components (fat, lactose and protein) in human breast 
milk, fat is the most variable. The fat in breast milk provides about 50 % of infants’ en-
ergy intake. Most of the FA are saturated, with a predominance of palmitic acid (16:0). 
The major fat content consists of triglycerides, while phospholipids and cholesterol are 
a minor part. The fat content increases during the feeding; fat levels are thus two to 
three times lower in foremilk than in hindmilk. Hindmilk consequently supplies 25 to 
35 kcal / 100 ml more energy, on average, than foremilk 148,149. The fat content is highest 
in colostrum, decreasing during the transition to mature milk. The LCPUFA and EFA 
content depends both on the mother’s diet and adipose tissue 152. 
1. 3. 3. Carbohydrates in breast milk 
The principal carbohydrate in human breast milk is the disaccharide lactose. The con-
centration of lactose is the least variable of the macronutrient concentrations in breast 
milk but milk lactose is positively correlated with milk volume 145. The other signifi-
cant carbohydrates in breast milk are the oligosaccharides, which comprise approxima-
tely 5 - 15 g/L, depending on lactation stage and maternal genetic factors. The oligo-
saccharides are considered to be non-nutritive and bioactive. They are prebiotic agents 
that selectively encourage the growth of beneficial (probiotic) organisms. Furthermore, 
the oligosaccharides and their protein conjugates are recognized as pathogen-binding 
inhibitors that function as soluble “decoy” receptors for pathogens with an affinity for 
binding to oligosaccharide receptors expressed on the infant’s intestinal surface 144.
1. 3. 4. Micronutrients in breast milk
Many micronutrients, including vitamins A, B1, B2, B6, B12, D and iodine, vary in 
human milk, depending on maternal diet and physique. Vitamin K levels are extremely 
low in human milk and many countries recommend an injection of this vitamin in order 
to avoid hemorrhagic disease of the newborn. Vitamin D levels are also low in breast 
milk, particularly with low maternal exposure to sunshine. Current pediatric recom-
mendations prescribe postnatal vitamin D supplementation until at least two years of 
age 153,154. 
1. 3. 5. The breast milk microbiome
Several studies have demonstrated that breast milk from healthy women contains app-
roximately 103-104 colony-forming units (cfu)/ml, representing a continuous source 
of potential commensal bacteria for the infant gut 155. More than 200 different bacterial 
species have been isolated from human milk. Traditionally, it is believed that the pre-
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sence of bacteria in breast milk is a result of contamination from the mother’s skin or 
the infant’s oral cavity, but there must also be other pathways to the breast. Bifidobac-
teria present in breast milk are strict anaerobes; it is thus unlikely that they are trans-
ported from the infant’s mouth to the skin of the breast 156. Bacteria can also be isolated 
from colostrum before the infant is born and live bacteria orally administered to lacta-
ting women can be retrieved from breast milk 157,158. One possible route for microbes 
to the breast is massive migration from the maternal intestinal tract, with subsequent 
uptake by different immune cells 159.
1. 4. Weight gain in pregnancy 
Limiting gestational weight gain (GWG) to the recommended level is important in 
order to optimize maternal and neonatal health outcomes. A retrospective cohort study 
by Vesco et al, including 2 080 obese women, showed that GWG above that recom-
mended by the American Institute of Medicine in 2009 160 did not significantly decrea-
se the SGA risk but was associated with an increased odds both of macrosomia (OR 
3.36; 95  % CI 1.74 - 6.51; 6.0 % vs. 2.1 %) and large for gestational age (LGA) (OR 
1.80; 95 % CI 1.36 - 2.38; 23.8 % vs. 16.6 %). GWG below that in the recommendations 
was associated with increased odds of SGA (OR 3.94; 95 % CI 2.04 - 7.61; 8.8 % vs. 
2.7 %) and decreased odds of LGA (OR 0.56; 95 % CI 0.37 - 0.84; 11.2 % vs. 16.6 %). 
Table 1 shows the American Institute of Medicine recommendations for GWG in obese 
women.
A 2007 study from the Swedish Medical Birth Register found that the optimal GWG 
was 4 - 10 kg for women with initial BMI less than 20, 2 - 10 kg for BMI 20 - 24.9, less 
than 9 kg for BMI 25 - 29.9 and less than 6 kg for BMI 30 or more, based on significant 
risk estimates of adverse maternal and fetal outcome 161.
GWG is strongly associated with postpartum weight retention, i.e. not returning to 
pre-pregnancy weight within six months after delivery. For some women, GWG is a 
trigger for developing overweight and obesity 162. 
1. 5. Physical activity in pregnancy
There is strong evidence of health benefits related to PA (Physical Activity) in pregnan-
cy, for example reduced risk of preeclampsia163, gestational diabetes 163,164 and preterm 
birth 165. The lower rate of prematurity may be related to reduced oxidative stress and 
Table 1. Recommendations for total and rate of weight gain during pregnancy, by 
prepregnancy BMI
Prepregnant Weight 
Category
BMI Recommended 
Range of total Weight
Recommended Rates of 
Weight Gain† in the Second 
and Third Trimesters (kg) 
(Mean Range [kg/week])
Underweight Less than 18.5 13 - 18 0.5 (0.45 - 0.59)
Normal Weight 18.5 - 24.9 11 - 16 0.5 (0.36 - 0.45)
Overweight 25 -29.9 7 - 11 0.3 (0.27 - 0.32)
Obese 30 and greater 5 - 9 0.2 (0.18 - 0.27)
* Calculations assume a 0.5 - 2 kg weight gain in the first trimester (based on Sie-
ga-Riz et al., 1994; Abrams et al., 1995; Carmichael et al., 1997)
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the lower incidence of preeclampsia may be associated with exercise 166. Regular ex-
ercise appears to increase antioxidative enzymes in pregnant women, which in turn 
reduces oxidative stress and preeclampsia. These may be contributing factors to the 
reduced prematurity rate reported for exercisers versus non-exercisers.
Decreasing PA and more depressed mood are common during pregnancy 167. Studies 
from several different countries suggest that only about 40 % of pregnant women ex-
ercise. Positive factors for exercising more during pregnancy include higher education 
and income, not having other children in the home, being white and being more active 
prior to pregnancy 168.  A randomized study from Sweden showed that a water aerobics 
program was more effective than a land-based physical exercise program in decreasing 
pregnancy-related low back pain 169. Reducing physical discomfort, increasing mobili-
ty, improving body image and increasing health-promoting behaviors are other positive 
effects of similar programs 170. Several studies have reported positive effects of yoga 
in pregnant women, including less stress, anxiety and pain during pregnancy 171. USA 
exercise guidelines recommend that all healthy women undertake at least 150 min of 
moderate-intensity aerobic activity a week during pregnancy 172.
1. 6. Interventions aimed at limiting gestational weight gain
Many interventions have been conducted with the aim of limiting GWG to appropriate 
levels. A meta-analysis by Thangaratinam et al reported that mean GWG in the com-
bined intervention groups was 1.4 kg lower than in the control groups. Only PA was 
associated with reduced birth weight (mean difference - 60 g). Taken together, the inter-
ventions were associated with a reduced risk of preeclampsia (OR 0.74; 95 % CI 0.60 
to 0.92) and shoulder dystocia (OR 0.39; 95 % CI 0.22 to 0.70). No significant effect 
was found concerning other critically important outcomes. Diet-based interventions 
were the most effective; they were associated with reductions in GWG and improved 
obstetric outcomes 173. A Cochrane review published in 2012 suggested that, analyzed 
together, the studied interventions had limited effect, as only a small reduction in total 
GWG had been found 174.
Hil et al undertook a systematic review evaluating the theories of behavior change 
informing GWG interventions; 19 studies were identified for inclusion. Eight studies 
were informed by a behavior change theory. Studies based on theory were as effecti-
ve as non-theory-based studies at limiting GWG. They showed that the interventions 
were effective at limiting GWG, with the intervention groups gaining significantly 
less weight than the control groups (weighted mean difference = - 1.54 kg). Seven of 
the reviewed studies showed significantly less GWG in the intervention group, whi-
le the other studies had found non-significant differences. Dietary interventions were 
significantly more effective at limiting GWG than both PA and mixed interventions. 
The provision of information, motivational interviewing, behavioral self-monitoring 
and providing rewards contingent on successful behavior appear to be key strategies in 
GWG interventions.
1. 7. Intervention research
In the book “Intervention research” Frasier et.al states that intervention research is 
a dynamic process involving researchers, agencies and practitioners: “As purposeful 
actions, interventions may operate at the individual, family, organizational, neighbor-
hood, regional, national or other level”.
Interventions may be comprised of a single action or a cluster of actions 175. 
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Intervention research has different purposes. Through intervention research, programs 
are developed and refined. It is a systemic process in which research findings, theory 
and practice knowledge are conjoined to create new programs or to modify existing 
ones. Intervention research attempts to ascertain whether a program is effective and 
produce the desired outcomes. Intervention research findings can inform theory, clari-
fy what made the program work and conclude that a program, rather than some other 
factor, has caused an observed outcome. 
According to Frasier, there are five steps in intervention research:
1. Specify the problem and develop a program theory
2. Create and revise program materials
3. Refine and confirm program components
4. Assess effectiveness in a variety of settings and circumstances
5. Disseminate findings and program materials
Step 1 involves the detailed description of a problem, a target population and a change 
process. In most cases, the first step in problem specification is to measure its incidence 
and prevalence. Is the prevalence rising? The demographic characteristics, political 
and economic cost and social significance of the problem are identified. Prevalence 
data can demonstrate risk over time and identify high-risk populations. Subsequently, 
mediating factors and mechanisms are identified, the literature is reviewed and experts 
The intervention and
research cycle.
Step 1 - 3
 Figure 7. The intervention and research cycle
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are consulted.
Developing a program theory involves identifying those risk factors and protective 
factors which are malleable, capable of being influenced. Identifying the intervention 
level, setting, outcomes and developing a logic model are other components. The pro-
gram theory includes both proximal and distal outcomes as well as specifying a change 
model. The program theory is also called the change process or the theory of change. 
After creating a program theory with targeting factors that are feasibly changed through 
a series of intervention actions, a pilot study is performed. 
In step 2 program materials are developed and revised, based on critical reviews and 
findings from the pilot study (or studies). The initial task involves fully specifying the 
intervention and testing the components for feasibility. Program materials should be 
rooted in a theory of change or logic model. This step includes assessing the capacity 
of practitioners to implement and adhere to the proposed treatment plan. 
Step 3 Interventions often involve several components, each designed to address an 
important risk factor. In step 3, each component is tested, separately and in different 
combinations. A variety of designs may be used to estimate the effect of each major 
component or combinations of components 176. It is important to test each component, 
because one part of the intervention program may be substantially more effective, sub-
stantially more costly or more difficult to implement than the other parts. When step 3 
is complete, the key components should be well defined and the differential benefits of 
each component should be clear. 
In step 4, effectiveness is tested. Effectiveness trials are design to confirm intervention 
components in routine practice; the intervention is tested in a setting in which the re-
searchers may have limited control, on a broad heterogeneous sample. Since fidelity 
is a central part of effectiveness trials, step 4 often entails programs being supervised 
by on-site staff. The estimates are based on intention-to-treat (ITT) and efficacy subset 
analyses. ITT is the outcomes of all participants for whom the intervention is intended, 
regardless of whether they received all, part or none of the intervention. Efficacy subset 
analyses focus on estimating the treatment effect. 
Step 5 When intervention research is successful, it has a significant impact on soci-
al and health problems, if implemented widely. The intervention is only useful if it 
reaches the at-risk population, works as intended and is maintained over time. Dis-
semination of findings and materials is aimed at actively helping the intervention to 
spread. Diffusion, “letting it happen”, occurs more realistically by practice penetration. 
Programs with a high degree of practice penetration are, according to Rogers et al 177:
• Superior to services as usual
• Compatible with agency practices
• No more complex than existing services
• Easy to try (and reject if they fail), and 
• Likely to produce tangible results recognizable by authorities as important
1. 8. Motivational interviewing
Motivational interviewing (MI) is a client-centered, directive therapeutic style to en-
hance readiness for change by helping clients explore and resolve ambivalence about 
change 178. MI is a complex clinical style for eliciting the client’s own values and moti-
vations for change. It is far more about listening than telling, about evoking rather than 
instilling. MI communicates not, “I have what you need,” but instead, “You have what 
you need, and together we will find it.” Like other psychotherapies, MI is a complex 
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and skillful method that is learned over time.
MI practice rests on four general principles: 
• Expressing empathy for the client by accepting the client’s situation and recog-
nizing that ambivalence is normal
• Developing discrepancy between present behavior and personal goals or values, 
thereby encouraging the client to present reasons for change 
• Rolling with resistance to counteract presentation of reasons not to change
• Supporting self-efficacy of the possibility of change, and emphasizing client 
responsibility for choosing and carrying out change
Four processes can often be identified in MI counseling: 1. Engaging, creating an alli-
ance and mutual trust between client and counselor; 2. Focusing, an agreement on what 
to keep in focus; 3. Evoking, to elicit and support motivation for behavior change; and 
4. Planning, which is essentially goal-setting and focusing on how goals for behavior 
change might be reached 179.
MI has a solid evidence base to support its efficacy, and has consistently been shown to 
be more effective than no treatment or placebo control conditions 178. MI is a potential-
ly useful method to increase motivation for behavior change in pregnancy.
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2. Aims
The overall aim of this thesis is to study different aspects of obesity and its association 
with pregnancy, delivery and breastfeeding, applying both clinical and epidemiological 
methodology and, if possible, to increase our understanding of how to improve the care 
of obese women during pregnancy, delivery and breastfeeding.
2. 1. Aims of the studies
1. To investigate whether an intervention program was feasible, both for the pregnant 
women and the health care staff involved in the program, and whether it was safe 
for mother and child (Paper I).
2. To investigate the FA pattern in obese mothers’ breast milk and their neonates’ 
plasma, compared with the corresponding pattern in normal-weight mothers and 
their neonates  (Paper II).
3. To assess the risk of obstetric anal sphincter lacerations in relation to maternal 
obesity among primiparas. (Paper III).
4. To compare health care consumption and sick-listing among obese and nor-
mal-weight pregnant women (Paper IV).
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3. Methods and subjects
3. 1. Ethics
Ethical approval from the Research Ethics Committee at Karolinska Institutet was 
obtained prior to initiation of all studies: Paper I: dnr: 2006/1100-31/4; Paper II: dnr: 
2008/1427-31/3; Papers III and IV: dnr: 2008/1427-31/3. All patients gave their in-
formed consent to participate in the clinical studies (Papers I and II). The analyses in 
Papers III and IV were performed on the statistical group level; no specific patients 
could be identified.
3. 2. Paper I
This is a prospective pilot study. Twenty-seven pregnant women with BMI > 30 were 
enrolled in a dietary and PA program during their first trimester. Twenty-five women 
completed the program. One woman had Sjögren’s disease, one had ulcerative colitis 
and asthma, one had PCOS, two had been treated for hypertension, one had asthma and 
one had vitamin B12 deficiency. None of the women smoked during pregnancy. 
The program included visiting a midwife every fortnight throughout the pregnancy 
and participating in two group support sessions, where all participants in the program 
met and discussed their experiences, guided by a midwife. The program also included 
an individual consultation with a dietician at the beginning of pregnancy. Participants 
were instructed to eat according to ’the plate model’ 180 , aimed at minimizing unneces-
Table 2. Logic model of intervention study
Inputs Activities Materials Intermediate 
outcomes
Distal outcomes
Funding from 
Stockholm 
County council
Education of 
midwives from 
delivery board 
and mother 
healthcare cen-
ters.
Manuals to mid-
wives, doctors 
and dieticians
Increased know-
ledge in healthy 
food and physical 
activity during 
pregnancy.
Weight gain less 
than 6 kg during 
pregnancy
Expert supports Training in MI
Information’s 
to hospital staff 
and to other 
Mother Health-
care Centers
MI and weight 
control, Mother 
Healthcare 
Centers
Increased motiva-
tion in mothers 
Percentage of 
• Cesarean sec-
tion
• Preeclampsia
• Hypertension
• Macrosomia
Local resources Coaching Meeting with 
dietician, food 
diary
Increased confi-
dence in mothers
Questioners 
to patients: 
confi-dence, 
knowledge
Meeting with 
midwife from 
delivery ward
Water gymnastic
Exercise 30 
minutes/day
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sary calories, and to eat full meals at regular intervals. The women were recommended 
to keep a food intake diary, where everything they ate was recorded together with 
their PA. All patients in the program were offered water gymnastics once a week and 
they were required to exercise 30 minutes per day the other days of the week. If the 
pregnancy remained normal, the women consulted an obstetrician three times during 
pregnancy and at a follow-up visit six to eight weeks after delivery. Maternal BMI was 
calculated at inclusion and GWG was recorded at every consultation with the midwife. 
Pregnancy-induced complications were recorded in a separate protocol. Data on de-
livery outcomes were collected from the hospitals’ computerized charts and included 
mode of delivery, complications and birth weight. 
Blood was sampled on inclusion at the beginning of pregnancy and repeated at pregnan-
cy weeks 28-32 and 40. Blood samples were analyzed for Hb, serum total cholesterol, 
free FA, low- density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, 
folate, thyroid-stimulating hormone (TSH) and free thyroxin (fT4). Glycosylated he-
moglobin A1C (HbA1c) was tested at the beginning of pregnancy. In gestational week 
28-30, the participants had an oral glucose tolerance test (OGTT). All pregnancies were 
dated by ultrasound in gestational week 18-19 and all participants had two additional 
ultrasounds in gestational weeks 32 and 40. The Edinburgh Postnatal Depression Scale 
(EPDS) was used as a screening tool for detection of ante- and postnatal depression 181. 
3. 3. Paper II
The fatty acids pattern in breast milk and neonatal plasma was analyzed in an obser-
vational study of 41 obese and 41 normal-weight pregnant women. Twenty-nine obese 
women participating in a weight reduction program were included for comparison. In 
order to randomly include normal-weight and obese controls, they were included after 
a woman from the intervention study had been delivered. Thus, when a baby was born 
in the intervention group, the next mother with pre-pregnant BMI > 30 kg / m2 and with 
a baby of the same gender was invited to participate. If a woman declined to participa-
te (n = 4), the next woman fulfilling the criteria was contacted. The next woman with 
a BMI < 25 kg / m2 and a baby of the same gender was also asked to participate. For 
the last 12 infants born to the women in the intervention group, the number of control 
infants was doubled. 
The intervention was a weight control program, including general dietary advice and 
increased PA, and was introduced for pregnant obese women with BMI > 30, as previo-
usly described (Paper I). FA supplementation or intake was not discussed. The Swedish 
National Food Agency’s general recommendation for all pregnant women, was to eat 
fish two or three times a week; however, n-3 supplementation was not recommended. 
FA were analyzed with capillary gas chromatography of lipids in breast milk collected 
at three and ten days and one and two months postnatally, as well as in the infants’ plas-
ma phospholipids, sampled three days after birth. All mothers answered, while still in 
the neonatal ward, a short food frequency questionnaire concerning the intake of fish, 
eggs, and vegetables during pregnancy. The questionnaire also included fats used for 
spread and cooking, sweets and the daily number of full meals. On the third day after 
birth, simultaneously with the routine general neonatal screening, a blood sample was 
taken from the baby for the analysis of plasma phospholipid FA. The mothers were as-
ked to collect breast milk after nursing the baby (hindmilk) on days three and ten, and 
at one and two months after birth. Phospholipids and breast milk lipids were analyzed 
with capillary gas-liquid chromatography, as previously described 118.
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3. 4. Paper III
This is a population-based cohort study, based on Swedish Medical Birth Register data 
from January 1, 2003 to December 31, 2008, including 210,678 primiparas. Women 
with multiple gestations and cesarean sections were excluded. BMI was categorized 
into four classes: < 25, 25 -< 30, 30 -< 35 and > 35. The Swedish Medical Birth Regis-
ter has recorded data on more than 98 % of all deliveries in Sweden since 1973 and 
has previously been validated and described in detail 182. Starting with the first ante-
natal visit, normally at 8 - 12 weeks’ gestation, information on maternal demographic 
data, reproductive history, pregnancy and previous births is prospectively collected 
by a midwife. The record also includes maternal weight and height, from which BMI 
(kg / m2) is calculated. The standardized records are identical throughout the country 
and are forwarded to the Central Birth Register. In accordance with national guideli-
nes, perineal lacerations were diagnosed by the attending midwife who inspected the 
vagina immediately after childbirth. The diagnosis and classification of perineal la-
cerations follow the ICD-10: grade I, labial tears (ICD O70.0); grade II, perineal and 
vaginal laceration, but no anal sphincter involvement (ICD O70.1); grade III, partial or 
complete anal sphincter laceration (ICD O70.2); grade IV, complete anal sphincter la-
ceration including rectal mucosa (ICD O70.3). In cases in which the midwife suspects 
a grade III - IV laceration, the attending obstetrician is consulted to confirm or refute 
the diagnosis. Information on age at delivery, operative delivery, birth weight, head 
circumference and maternal diabetes mellitus was also obtained from the register.
3. 5. Paper IV
This retrospective population-based cohort study included all primiparas with a single-
ton pregnancy recorded from January 1, 2003 through December 2008 in the Swedish 
Medical Birth Register 182. The study population was linked to two other nationwide 
Swedish registers, the Swedish National Inpatient Register (IPR) and the Maternal 
Health Care Register. The final study population was required to be recorded both in 
the Swedish Medical Birth Register and the Maternal Health Care Register and consi-
sted of 108,103 primiparas. Information on sick-listing was only recorded from 2003 
and 2006-2008. Data on inpatient care was obtained from the IPR which has complete 
national coverage from 1987; more than 99 % of all somatic and psychiatric hospital 
discharges are registered. A previous validation of the IPR by the National Board of 
Health and Welfare showed that 85 - 95 % of all included diagnoses are valid 183. The 
Maternal Health Care Register was created in 1997 as a complementary database to the 
Medical Birth Register in order to measure antenatal health care quality. Between 2003 
and 2008, the Maternal Health Care Register contained information on 71 - 82% of all 
pregnancies, variations that are due to changes in national coverage. Midwives report 
data twice to the Maternal Health Care Register, at the beginning of the pregnancy and 
16 weeks after delivery. 
Health care consumption up until 7 days prior to delivery was studied in relation to 
BMI at the first antenatal care visit and included the number of visits to an obstetrician, 
the number of visits to a midwife, the number of visits to cross-disciplinary clinics for 
treatment of moderate to severe fear of childbirth (referred to as “Aurora clinics” in 
Sweden), sick-listing during pregnancy (obtained from the Maternal Health Care Re-
gister), the number of hospital admissions and the causes of in-patient care (obtained 
from the IPR).
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4. Statistical analyses
4. 1. Paper I
Fisher’s exact test was used to compare proportions. Wilcoxon’s matched pairs test was 
used to compare continuous non-parametric numeric data. Outcomes are presented for 
the entire group, as well as categorized by BMI at inclusion. p < 0.05 was considered 
significant for all analyses. Statistical analyses were performed using STATISTICA 
software (StatSoft Inc. Tulsa, OK).
4. 2. Paper II
To compensate for suspect skewness in the obese population, the Kruskal-Wallis 
non-parametric test was used to calculate differences in FA concentrations in plasma 
between infants in the three groups, and multiple comparisons of mean ranks for all 
groups was used for ad hoc analysis. Maternal and infant characteristics were compa-
red with the chi-squared test and ANOVA. Multiple regression analysis was used to 
calculate associations between FA compositions and food intake, smoking, n-3 supp-
lementation and other background factors, as well as to study the relationship between 
BMI at one year of age and FA in breast milk and infants’ plasma. ANOVA repeated 
measures were used to calculate differences in FA concentrations in breast milk and for 
ad hoc analysis of differences. The Bonferroni’s test was used for repeated measures 
analysis; only mothers who provided at least three samples were included. Statistical 
significance was set at p < 0.05 for each statistical hypothesis. Statistical analyses were 
performed using STATISTICA software (StatSoft Inc. Tulsa, OK).
4. 3. Paper III
Proportions for grade I - IV lacerations are presented as absolute numbers and propor-
tions with 95 % CI, according to BMI class. In order to estimate the effect of BMI on 
obstetric anal sphincter lacerations, with possible confounders accounted for, uni- and 
multivariate logistic regression analyses were performed. The univariate analysis used 
all the variables identified a priori as possible risk factors for anal sphincter lacerations, 
including BMI class, maternal age, instrumental delivery, birth weight, head circum-
ference and diabetes mellitus. Variables showing a significant relationship in the uni-
variate analysis were included in the final multivariate model. ORs were estimated 
with 95 % CIs. All statistical analyses were performed using SAS software (Cary, NC, 
USA).
4. 4. Paper IV
Women were grouped into four BMI categories: normal weight (20 -< 25); overweight 
(25 -< 30); obese (30 -< 35); and morbidly obese (>-35). For numerical variables, means 
and standard deviations are presented, whereas one-way ANOVA was used for testing 
the hypothesis of equal means. Pairwise comparisons among groups are obtained post-
hoc by the Tukey HSD test. For categorical variables, frequencies and percentages are 
presented. Where frequencies are presented, the p overall in the tables is from the R 
function probability test, a test of equal proportions. Also presented are p-values for 
pairwise comparisons among all BMI groups; these are Holm adjusted post-hoc tests 
by R function pairwise probability tests. All statistics were performed in R, version 
2.14.1. 
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5. Results
5. 1. Paper I
Twenty-five women (92 %) completed the study. Their mean age at entry was 31.7 
years and their median parity was 1 (range 0 - 3). Table 3 shows detailed patient cha-
racteristics, while clinical outcomes are presented in Table 4. Fifty-six percent (14 / 25) 
kept their GWG under the set goal of 6 kg, six (24 %) gained 7 - 11 kg and the re-
maining five (20 %) had a GWG of 12 - 20 kg. GWG was significantly lower among 
women with BMI  > 35, compared to women with BMI 30 - 35 (p  <  0.01). Antenatal 
assessment of fetal weight estimated ordinary growth. Oligohydramnios was observed 
in one case. All women delivered normal-sized babies with normal Apgar scores (8 - 10 
at one minute). ne baby was born with a cleft palate. Three women (12 %) were deliv-
ered by emergency cesarean section and one had an instrumental delivery, while the 
other 21 (84 %) were delivered vaginally without complications. Three women (12 %) 
were diagnosed with mild hypertension and there were no cases of reduced glucose 
tolerance. Five women had a TSH > 2.0 and received thyroxin treatment; one had thy-
roid peroxidase (TPO) antibodies and continued treatment after delivery.  There were 
no significant differences in triglycerides, cholesterol or the HDL/LDL ratio between 
women with GWG < 6 kg and those with > 6 kg, or between those with BMI 30 ≤ 35 
and those with BMI > 35. EPDS scores changed, from 4.6 (± 4 SD) at Maternal Health 
Care Center registration early in pregnancy, to 4.2 (± 3.5 SD) at 28 gestational weeks 
and to 5.6 (± 4.7 SD) after delivery (p = 0.5 and 0.9, respectively, in comparison to ba-
seline). Women with a GWG < 6 kg scored lower (4.0 ± 2.6 SD) than those who gained 
> 6 kg, but this difference was not significant (5.3 ± 5.2 SD; p = 0.8). The women were 
also asked to send in a questioner anonymously. 17 of the women answered and they 
all wrote that they would recommend the project to a friend, 16 patients scored how 
pleased they were with the project within the range of 9 - 10 to a 10 grade scale, one 
patient scored 5.5.
Table 3. Descriptive statistics at study entry.
Entire study 
group
BMI 30 - 35 BMI > 35
n = 25 n = 11 n = 14
Age (years)a 31.7 ± 3.2 32.2 ± 3.6 31.2 ± 2.9
BMIa 35.4 ± 4.4 33.4 ± 1.6 39.7 ± 4.2
Weight at admittance (kg)a 99.8 ± 15.0 91.5 ± 9.5 110.1 ± 14.0
Length (cm)a 164.8 ± 5.4 163.4 ± 5.7 166.3 ± 4.5
Parityb 1 (0 - 3) 1 (0 - 2) 1 (0 - 3)
Cesarean section (n) 3 1 2
Vaginal deliveries (n) 9 2 7
aMean ± SD. bMedian, range. 
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5. 2. Paper II
5. 2. 1. Mothers
Maternal characteristics are presented in Table 5. The obese mothers had a lower level 
of education and a higher rate of smoking before pregnancy. None had diabetes melli-
tus or had developed gestational diabetes. Nine patients in the intervention group and 
three in the normal-weight group were successfully treated for subclinical hypothy-
roidism during pregnancy; none of them had thyroid antibodies. Cesarean section was 
more common in the obese group (n = 11) and the intervention group (n = 6) than in the 
normal-weight group (n = 3). The obese group ate less fish and seafood than the other 
groups (p < 0.05 for each). Seven obese women, but only two in the normal-weight 
group and none in the intervention group, reported fish sticks as the main source of 
fish intake. There was no difference between the groups when it came to fats used for 
spread or cooking (data not shown). GWG was calculated as increase from pre-preg-
nancy weight to weight at 36 weeks, and was higher in the normal-weight group than 
among the obese women. It was not possible to calculate GWG for seven of the obese 
women, since they declined to be weighed during late pregnancy, suggesting that the 
GWG in this group was underestimated. The aim of GWG not exceeding 6 kg was 
almost reached in the intervention group (Table 5).
Table 4. Clinical outcomes.
Entire study 
group
BMI 30 - 35 BMI > 35
n = 25 n = 11 n = 14 P-valuea
Gestational weeksb 40 (35 - 41) 39 (35 - 41) 40 (37 - 41) 0.04
Pregnancy maternal 
weight gainb 
6.9 ± 6.4 8.5 ± 5.3 5.7 ± 7.0 0.001
Fetal ultrasoundb,d
Fetal growth week 32 2.6 ± 7.8 1.4 ± 5.3 3.6 ± 9.5 0.8
Fetal growth week 40 5.6 ± 14.4  - 3.7 ± 11.4 9.6 ± 14.4 0.2
Oligohydramniosis 1 1 0 0.9
Birth weight (g)b 3,484 ± 453 3,305 ± 328 3,611 ± 496 0.1 0.1
Preterm deliveryc 1 1 0 0.2
Mode of deliveryc
Vaginal birth (%) 22 8 14 0.04
Emergency cesarean sec-
tion (%) 
3 3 0 0.04
Elective cesarean section 
(%) 
0 0 0  - 
Pregnancy induced com-
plicationsc
Hypertension 3 1 1 0.9
Symphyseolysis 2 1 1 0.9
Preeclampsia 0 0 0  - 
Hepatosis 0 0 0  - 
aP-value for comparison between women with BMI 30 - 35 and women with BMI > 35 
using bWilcoxon matched pairs test or cFisher’s exact test.
dFetal ultrasound presented as % deviation from the normal distribution curve.
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5. 2. 2. Neonatal period and 
growth
Data on the infants are shown in Table 6. 
Birth weight, birth length, head circum-
ference and ponderal index (kg / m3) did 
not differ between groups. One baby in 
each group had a birth weight of ≥ 4.5 kg, 
and one baby in the intervention group 
and four in the obese group were LGA. 
One baby in the obese group, but none 
in the normal-weight or intervention 
groups, was SGA. There were no diffe-
rences in immediate neonatal outcome 
in the groups; two infants in the obese 
group were observed for three days in 
the neonatal ward, and one baby in the 
normal-weight group was jaundiced and 
required short-term daylight therapy. The 
duration of breastfeeding was similar in 
the three groups (Table 6), and formula 
was only occasionally given to some in-
fants during the first days of life. Three 
women in the normal-weight group, two 
in the obese group and two in the inter-
vention group breastfed for less than one 
month. There was no difference in infant 
weight, length or BMI at 12 months of 
age and no correlation between BMI at 12 
months and duration of breastfeeding, pa-
ternal or maternal BMI, FA pattern in bre-
ast milk or early plasma phospholipids.
5. 2. 3. Plasma phospholipid 
fatty acid pattern in the infants
There were minor differences between 
saturated (SFA) and monounsaturated 
(MUFA) FA levels between groups; SFA 
were highest and MUFA were lowest in 
the normal-weight group (Table 7). The 
plasma concentrations of LA were higher 
in babies in the intervention group than 
in the normal-weight and obese groups 
(p < 0.01 for both differences).Total n-3 
FA, including EPA and a-linoleic acid 
(18:3 n - 3, LNA), were lowest in the obe-
se group. All ratios between n-6 FA and 
n-3 FA were highest in the obese group, 
with smaller but significant differences 
between the normal-weight and interven-
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Figure 8. Molar percentage of total n-3 
FA (upper part), the n-6/n-3 ratio (central 
part) and the ARA / DHA+EPA ratio (low-
er part) in consecutive breast milk sam-
ples from mothers in the normal-weight 
group (closed circles; n=17); obese group 
( triangles; n=17 ) and intervention group 
(open circles; n=10). Only milk from 
mothers who provided three or more milk 
samples are included in the figure.
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Table 5. Characteristics of the mothers, group C (BMI < 25 kg/m2), Group O (BMI 
> 30 kg/m2), group I (BMI > 30 kg/m2) with intervention, see text. Paternal BMI is 
also given.
BMI < 25 kg/m2 BMI > 30 kg/m2 BMI > 30 kg/m2 P-value
Normal weight No intervention Intervention
Age, years, mean ±SD 32.0±4.1 30.5±5.7 32.1±3.7
Pre-pregnancy BMI, 
mean±SD
22±1.8 35±3.8 36±5.0 b,e
Weight gain in pregnancy to 
week 36, kg, mean±SD 
13.2±3.8 9.5±5.8 6.6±3.3 b,d
Nullipara, % 61 44 41
Smoking, n
Until pregnancy 2 12 1 b,e
During pregnancy 1 3 0
Education, n
Elementary school 1 4 2
University 6 0 5
Intake of seafood, n
None 6 21 2
> 2 times/month 26 15 20 a,c
≤ 2 times/week
> 2 times/week 9 5 7
Intake ofOmega-3capsules,n 4 5 2
Paternal BMI, mean±SD 24±0.4 26±0.4 27±0.4
a p < 0.05 between C and O groups. b p < 0.01 between C and O groups. c p < 0.05 between O and 
I groups. d p < 0.05 between C and I groups. e p < 0.01 between C and I groups.
Table 6. Infant characteristics including duration of breast feeding. Infants are 
grouped in relation to maternal BMI. No significant differences between the groups. 
Mean ± SD
BMI < 25 kg/m2 BMI > 30 kg/m2 BMI > 30 kg/m2
Normal weight No intervention Intervention
n 41 41 29
Gestational age (weeks) 39.6 ±1.2 38.8 ±1.6 39.5 ±1.6
Birth weight (g) 3490 ±424 3605 ±494 3525 ±465
Birth length (cm) 49.7 ±1.4 49.4 ±1.7 49.5 ±2.0
Head circumference (cm) 35.1 ±1.5 34.8 ±1.6 34.9 ±1.1
Ponderal index at birth (kg/
m3)
2.9 ±0.2 2.8 ±0.2 2.9 ±0.2
Weight / gestational age > 2 
SD (n)
0 4 1
Weight/length > 2 SD (n) 1 7 5
Breast feeding, months 4.1 ±1.9 4 ±0.6 3.9 ±1.9
Any formula fed at day 1-3 
(n)
6 11 8
BMI at 12 months (kg/m2) 17.6 ±0.8 17.6 ±0.8 17.0 ±1.6
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tion groups (Table 7). Levels of significance are shown, excluding smokers, although 
smoking did not influence the significance of the differences between groups.
5. 2. 4. Fatty acid pattern in breast milk 
The number of mothers providing milk samples was 26 / 41 in the normal-weight group, 
25 / 41 in the obese group and 25 / 29 in the intervention group. Three and four milk 
samples were provided by 17 mothers in the normal-weight and obese groups, respec-
tively, and by 10 in the intervention group. Only results from those mothers providing 
three samples or more are included in Fig. 8. On day three, SFA concentrations were 
highest in the milk from the normal-weight group, but levels were highest in the obese 
group in subsequent samples (p < 0.01). MUFA levels were highest in the obese group 
on day three, but not later on. The concentrations of n-6 FA were highest in the nor-
Table 7. Major fatty acid pattern in babies’ plasma phospholipids at three days after 
birth. Infants are grouped according to maternal BMI. (Mean ± SEM in mol %).
BMI < 25 kg/m2 BMI > 30 kg/m2 BMI > 30 kg/m2
Normal weight No intervention Intervention
n = 21 n = 27 n =11
 Mean + SEM Mean + SEM Mean + SEM
∑SFA 54.26±0.03## 53.84±0.03 53.20±0.07**
- 14:0 0.27±0.01## 0.23±0.01 0.30±0.01*
-16:0 36.17±0.23 36.13±0.23 35.52±0.22
-18:0 15.05±0.14 14.91±0.21 15.08±0.14
∑ MUFA 13.09±0.02## 13.37±0.03 13.30±0.04
-18:1n9 10.06±0.02 10.42±0.02 10.37±0.03
∑ PUFA 32.66±0.03 32.93±0.03 33.63±0.07**§§
-20:3n9 0.26±0.02 0.29±0.03 0.18±0.03*
∑ n6 26.52±0.04## 27.42±0.04 27.70±0.07*§§
-18:2n6 (LA) 8.37±0.07 8.90±0.06 10.82±0.14**§§
-20:3n6 2.52±0.09 2.58±0.09 2.39±0.08
-20:4n6 (ARA) 15.37±0.05## 15.73±0.03 14.22±0.01**
∑ n3 5.88±0.02## 5.22±0.02 5.75±0.02**
-18:3n3 (LNA) 0.04±0.00 0.03±0.01 0.08±0.00**
-20:5n3 (EPA) 0.68±0.05## 0.46±0.05 0.71±0.04**
-22:6n3 (DHA) 5.15±0.02## 4.72±0.02 4.96±0.02
Ratios
ARA/DHA+EPA 2.72±0.01## 3.11±0.01 2.60±0.02**
LA/LNA 264.84±2.60## 308.01±1.60 251.28±2.90**§§
ARA/EPA 26.45±0.21## 39.14±0.27 27.30±0.44**
n6/n3 4.71±0.02## 5.52±0.03 5.02±0.03**§§
SFA, saturated fatty acids; MUFA, mono-unsaturated fatty acids; PUFA, poly-unsa-
turated fatty acids; n6, omega-6 fatty acids;n3, omega-3 fatty acids; ARA, arachi-
donic acid; DHA, docosahexaenoic acid; EPA, eicosa-pentaenoic acid; LA, linoleic 
acid; LNA, Alfa-linoleic acid. Significant differences between normal weight group 
and obese group are expressed as # p < 0.05, ## p < 0.01. Differences between 
intervention and obese groups are expressed as * p < 0.05, ** p < 0.01. Differen-
ces between intervention and normal weight group are expressed as § p < 0.05, §§ 
p < 0.01.
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mal-weight group on day three and n-3 FA levels were lowest in the obese group at re-
peated measurements (p < 0.01). This was also true for LNA, EPA and DHA, the latter 
explained by the low fish intake in the obese group (p < 0.01) (Table 8) . The n-6/n-3 
ratio was highest in the obese group, compared to the two other groups (p < 0.01). 
Furthermore, the ARA/EPA + DHA ratio was significantly higher in the obese group 
than in the normal- weight group and intervention groups in repeated milk samples 
(p < 0.01) (Fig. 8).
5. 3. Paper III
Almost 8 % of the study population had a BMI > 30 kg/m2 and were thus considered to 
be obese. The distribution according to BMI class is presented in Table 9. The mean 
age of the study population was 27 years, with only minor differences between the BMI 
classes. The prevalence of the various perineal lacerations in relation to BMI category 
is presented in Table 10. In total, 8 958 (4.25 %) cases of anal sphincter lacerations, de-
fined as grade III - IV perineal lacerations (see Introduction), occurred. The respective 
proportions of women with anal sphincter lacerations were 4.25 % among those with 
BMI < 25 kg / m2, 4.3 % among those with BMI 25 to <  30 kg/m2, 4.03 % among those 
with BMI 30 to < 35 kg / m2 and 3.71 % among those with BMI > 35 kg / m2. There were 
very few anal sphincter lacerations involving the rectal mucosa (0.17 %). With regard 
to grade I and II lacerations, there was an almost linear increase in the occurrence of 
injuries related to increasing BMI. In contrast, the occurrence of anal sphincter lace-
rations showed an overall inverse correlation with increasing BMI. Univariate logistic 
regression analyses identified increasing BMI, age, instrumental delivery, birth weight 
and head circumference as risk factors for both grade I - II and grade III - IV lacerations. 
Maternal diabetes was not found to have a significant effect on the risk of lacerations, 
regardless of severity, and was therefore not included in the final multivariate model. 
When the independent variables (age, instrumental delivery, fetal weight and head 
circumference) were included in a multivariate setting (Table 11), increasing BMI 
showed a nearly dose - response protective effect against grade III - IV lacerations. At 
the same time, increasing BMI was associated with a dose - response type of increa-
se in the risk of grade I - II lacerations. The greatest risk of anal sphincter laceration 
was observed among women undergoing an instrumental delivery (OR, 2.92; 95 % CI, 
2.78 - 3.06) which, at the same time, decreased the risk of grade I - II lacerations (OR, 
0.77; 95 % CI, 0.75 - 0.79). In our study, we found that 15.3 % of all women underwent 
an instrumental delivery, the occurrence of which was nearly identical throughout the 
BMI classes: BMI < 25 kg / m2, 15.1%; BMI 25 to < 30 kg / m2, 16.4 %; BMI 30 to < 35 
kg / m2, 14.3 %; BMI > 35 kg / m2, 15.2 %. The significant effect of head circumference 
which, in the univariate analysis, was associated with both grade I - II (OR, 1.08; 95% 
CI, 1.07 - 1.09) and grade III - IV (OR, 1.20; 95 % CI, 1.19 - 1.22) lacerations, was at-
Table 9. Distribution of individuals over BMI group
BMI class Frequency (n) Percent Age mean(SD)
< 25 148826 70.64 27.1 (4.8)
25 -< 30 45055 21.39 27.4 (4.9)
30 -< 35 12352 5.86 27.2 (5.0)
>-35  4445 2.11 27.3 (5.0)
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tenuated to a non-significant level in the multivariate analysis (Table 11). Increasing 
birth weight increased the risk of anal sphincter lacerations, and a dichotomized birth 
weight of 4.5 kg or more (n = 4115) was associated with a more than doubled risk, com-
pared to a birth weight of < 4.5 kg (OR 2.40; 95 % CI, 2.17 - 2.66).
5. 4. Paper IV 
The study population prevalence of overweight (BMI 25 - 29.9) was 25.4 %, of obesity 
(BMI 30 - 34.9) 7.6 % and of morbid obesity 3.2 % (BMI ≥ 35). Maternal characteristics 
according to BMI class are presented in Table 12. There were small but statistically 
significant increases in the number of visits to both obstetrician and midwife with in-
creasing BMI category, compared to normal-weight women (Table 13). The number of 
women referred to an Aurora clinic (see above) increased with increasing BMI and was 
significantly more common, compared to 3.6 % in normal-weight women (p  <  0.001 
for all comparisons) (Table 13). The number of sick-listed women during pregnancy 
Table 11. Univariate and multivariate logistic regression analyses for the associa-
tion between body mass index (BMI) and perineal lacerations.
Univariate Multivariate
OR 95% CI p-value OR 95% CI p-value
Grade I-II obstetrical 
lacerations
BMI 1.03 1.03-1.03 <0.0001
< 25 1.00 1
25 ≤ 30 1.17 1.14-1.19 <0.0001 1.13 1.11-1.16 <0.0001
30 ≤ 35 1.24 1.19-1.29 <0.0001 1.23 1.11-1.16 <0.0001
> 35 1.34 1.25-1.43 <0.0001 1.32 1.23-1.41 <0.0001
Age (years) 1.07 1.07-1.08 <0.0001 1.07 1.07-1.08 <0.0001
Instrumental delivery (yes/
no)
0.89 0.87-0.92 <0.0001 0.77 0.75-0.79 <0.0001
Fetal birth weight (g) 1.00 1.00-1.00 <0.0001 1.00 1.00-1.00 <0.0001
Head circumference (cm) 1.08 1.07-1.09 <0.0001 1.06 1.05-1.07 <0.0001
Grade  I-IV obstetrical 
lacerations
BMI 1.00 0.99-1.00 0.68
< 25 1 1
25 ≤ 30 1.03 0.98-1.09 0.25 0.89 0.85-0.95 <0.0001
30 ≤ 35 0.95 0.86-1.04 0.25 0.84 0.76-0.92 <0.0004
> 35 0.87 0.74-1.01 0.08 0.70 0.59-0.82 <0.0001
Age (years) 1.06 1.05-1.06 <0.0001 1.05 1.05-1.06 <0.0001
Instrumental delivery 
(yes/no)
3.42 1.05-1.06 <0.0001 2.92 2.78-3.06 <0.0001
Fetal birth weight (kg) 3.03 2.90-3.17 <0.0001 2.86 2.70-3.02 <0.0001
Head circumference (cm) 1.20 1.19-1.22 <0.0001 0.99 0.98-1.01 0.82
CI, confidence interval; OR, odds ratio.
Birthweight and head circumference were measured immediately after birth.
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Table 13. Health care consumption during pregnancy
BMI 20 -< 25 25 -< 30 30 -< 35 35 - Total
n 68,884 27,461 8,296 3,489 108,103
n (year 2003, 
2006  -  2008)
42,979 17,155 5,234 2,245 67,613
Mean no. of 
hospital admis-
sion (SD)
0.1 (0.4) 0.1 (0.5) ** 0.2 (0.5) **¶¶ 0.2 (0.6) **¶¶†† 0.1 (0.5)
Mean no. of 
days admitted 
to hospital 
(SD)
0.5 (2.7) 0.5 (2.8) 0.7 (3.2) **¶ 0.9 (3.3) **¶¶† 0.5 (2.8)
Mean no. of 
visits to phy-
sician at mater-
nal health care 
center (SD). )
(Year 2003, 
2006-2008)
3.1 (1.6) 3.3 (1.8) ** 3.4 (1.9) **¶¶ 3.6 (2.2) **¶¶†† 3.2 (1.7)
Mean no. of 
visits to mid-
wife at mater-
nal health care 
center (SD)
10.9 (2.3) 11.1 (2.5) ** 11.4 (2.8) **¶¶ 11.7 (3.1) **¶¶†† 11.0 
(2.4)
No. of women 
sick-listed 
during preg-
nancy (%). 
(Year 2003, 
2006-2008)
9,003 
(22.4%)
4,264 (26.6) ** 1,475 (30.1) **¶¶ 720 (34.6%) **¶¶† 15,462 
(24.5)
Referred to 
Aurora clinic 
n (%)
3,073 (4.5%) 1,920 (4.7) 426 (5.2) * 232 (6.6) **¶¶†† 5,021 
(4.6)
Legends: * denotes significant difference between BMI 20 -< 25 and other groups. 
¶ between 25 -< 30 and † between 30 -< 35. Single legends denotes significance at 
level < 0.05, double legends denotes significance at the < 0.01 level.
An Aurora clinic is a cross-disciplinary unit for treatment of moderate to severe fear 
of childbirth.
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increased significantly with increasing BMI. Obese women were significantly more 
often admitted to hospital during pregnancy and had longer average in-hospital stays, 
compared to normal-weight and overweight women (Table 14). Stratifying for smoking 
did not change any result in Table 15. In-patient care during pregnancy and related di-
agnoses, in relation to BMI category, are shown in Table 14. The five most common di-
agnoses for in-patient care during pregnancy were pregnancy-induced abdominal pain 
(0.70 %); premature contractions without cervical ripening (0.62 %); vaginal bleeding 
(0.55 %); imminent premature labor (0.54 %); and hyperemesis gravidarum (0.53 %). 
However, none of these diagnoses showed a positive association with increasing BMI. 
On the contrary, being overweight and obese significantly reduced the occurrence of 
imminent premature labor (p <  0.001 for both BMI categories), in comparison with 
normal-weight women. 
The prevalence’s of pregnancy-induced hypertension, preeclampsia and gestational 
diabetes increased significantly with increasing BMI, compared to normal-weight wo-
men (p < 0.001 for all comparisons). Preeclampsia was more than six times as common, 
hypertension seven times as common, and gestational diabetes 14 times as common 
among obese as among normal-weight women (p < 0.001 for all comparisons). Becau-
se tobacco smoking was nearly twice as common before and during pregnancy among 
obese women, compared to normal-weight women, (Table 12), we performed a com-
plementary analysis of the causes of in-hospital care, from which smokers before and 
during pregnancy were excluded (Table 15). This analysis yielded essentially unaltered 
patterns in pregnancy-related morbidity as well as in the overall prevalence and pro-
portions of the various diagnoses.
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6. Discussion 
6. 1. Paper I 
Maternal obesity during pregnancy is an established risk factor for a variety of adverse 
maternal and neonatal outcomes 32. Almost 60 % of the patients participating in our die-
tary and behavioral intervention program achieved the á priori goal of a GWG less than 
6 kg. In this context, a weight increase of 6 kg essentially comprises the weight of the 
fetus, uterus, placenta and amniotic fluid, which means that not only did the majority 
of patients not gain any weight, but that some even lost weight during pregnancy. The 
reason that women with BMI > 35 were more successful in their weight control remains 
unknown but a higher level of motivation might be one explanation. 
We find our main results encouraging, considering that the observed 6 - kg GWG limit 
was accompanied by a low rate of complications related to pregnancy and delivery. 
The food and exercise diaries confirm that the women obtained sufficient nutrients. 
During pregnancy, obese women are at increased risk of gestational diabetes, hyper-
tension and preeclampsia. In this study, there were two cases of hypertension and one 
case of preeclampsia, all mild forms not requiring treatment. Two of the women were 
being treated for hypertension before pregnancy. Furthermore, there were no cases of 
gestational diabetes and both HbA1c levels and OGTT results were in the normal range 
for all patients, even those who failed to achieve the GWG goal. This indicates that the 
dietary and physical changes involved in the program may have beneficial metabolic 
effects, although they do not necessarily result in optimal weight control.
The most common medical condition necessitating treatment among our patients was 
hypothyroidism, which also was relatively frequent before pregnancy. There is insuf-
ficient evidence to support population-based screening for subclinical hypothyroidism 
but it is regarded as appropriate in pregnant women and patients at high risk of thyroid 
dysfunction 184. The prevalence of subclinical hypothyroidism in obese women is not 
fully known, but thyroid function, including within the reference range, has been asso-
ciated with body weight 185 and blood pressure 186 in women. Increasing levels of TSH 
have also been associated with less favorable lipid concentrations 187. Our findings of 
a high rate of hypothyroidism in obese women during pregnancy may have implica-
tions for pregnancy outcome, and postpartum maternal obesity, and warrants further 
investigation. In this study, the upper TSH limit was 2.0 mIE / L in the first trimester. 
However, there were two patients who had TSH levels above 2.5 mIE / L, the limit sti-
pulated by the American Thyroid Association 184.
Our weight limitation program was associated with satisfactory perinatal outcomes. 
There were no cases of IUGR or LGA. All infants had normal birth weights and were 
delivered at term with normal Apgar scores, except one case of preterm birth in week 
35 (this woman had given birth in week 32 in a previous pregnancy). In summary, it 
seems that weight control, and even intentional weight loss, in obese pregnant women 
does not generate adverse fetal outcomes. 
All patients in the program attempted spontaneous vaginal delivery and our cesarean 
section rate of 12 % is considerably lower than that described by Burstein et al (nearly 
33 %) 188. The lower cesarean rate in our patients should probably not be attributed to 
weight control per se, but rather to the secondary effects of the low rate of gestational 
complications commonly found among obese women. Also, most patients participa-
ting in the study were motivated and received regular support from the midwives in the 
program. This kind of individual and group support sessions may have contributed to 
the fact that none of our patients requested elective cesarean section.    
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During normal pregnancy, levels of plasma lipids, cholesterol and triglycerides increase 
during the second and third trimesters as a normal physiological response. Compared 
to non-pregnant levels, cholesterol may rise by 50 %, whereas triglyceride levels may 
increase by as much as 400 % in the third trimester 189. However, very little is known 
about lipid metabolism in obese pregnant women. We found a lipid pattern in our 
group of obese pregnant women similar to that in non-obese women, with significant 
increases in cholesterol and triglyceride levels during the second and third trimesters. 
The LDL/HDL ratio did not change significantly during pregnancy and it remains to be 
determined whether increased HDL levels are desirable during pregnancy with regard 
to cardiovascular effects and the risks of hypertension and preeclampsia 190. 
Obese women are generally at increased risk of depression, compared to normal-weight 
women 191. In our group of obese women, overall EPDS scores were stable throug-
hout pregnancy. However, the patients who gained the most weight during pregnancy 
also scored the highest in the EPDS, showing that there may be an association, albeit 
non-significant (p = 0.8), between depressive symptoms and weight increase among 
obese women. Although the cause-effect relationship needs to be disentangled, this 
association provides further ground for monitoring women with excessive weight gain 
during pregnancy more closely.
The lack of a control group is a drawback of our study; although our clinical data are af-
firmative, the efficacy of the proposed intervention program, compared to not offering 
any intervention at all, remains unproven. We also recognize that the relatively small 
population sample has implications for the statistical strength of our observations and 
may create limitations primarily involving detection of less common outcomes. The 
participants’ meals and exercise were not evaluated in this study. In the retrospect we 
could have evaluated the food diary more closely, possibly used food questionnaires, 
and also for example pedometers, which might have provided additional information, 
about to which extent the women really changed their eating and exercise habits. The 
intervention program was demanding in terms of health care resource consumption, 
particularly concerning the time invested by involved staff. A highly dedicated staff of 
midwifes and obstetricians may have contributed to the advantageous outcomes. This 
high level of commitment may not be available if the intervention program is under-
taken in other settings. Our results may therefore not be generalizable to health care 
in all contexts until large randomized controlled studies are performed. However, we 
believe that the study is nonetheless important since it clinically corroborates previous 
epidemiological research suggesting beneficial effects of minimizing GWG in obese 
women161.  
6. 2. Paper II
This observational study is one of the first reports showing differences in the concentra-
tion of FA in breast milk of obese mothers without diabetes, compared to mothers with 
normal BMI. Women with diabetes were excluded, since low concentrations of n-3 FA 
have been found in pregnant diabetics 192 .Only one similar study, from Argentina, has 
been published previously 139. All participants in that study had very high concentra-
tions of n-6 FA in breast milk, compared to those in our study, but the difference in the 
n-6/n-3 FA ratios between obese and normal-weight mothers was similar to that in our 
study. The significant differences in our study were especially marked for n-3 LCPU-
FA, which resulted in a more than 40 % higher n-6/n-3 ratio in breast milk from obese 
mothers, compared with breast milk from normal-weight mothers. In the intervention 
group, in which the obese pregnant women were given general dietary recommenda-
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tions concerning healthy food and regular meals combined with moderately increased 
PA, the n-6/n-3 FA ratio was more similar to that in the normal-weight group. Similar 
differences were also found in the infants’ early plasma phospholipids. Breast milk 
mainly reflects maternal diet 133, but the differences in FA concentrations between obe-
se mothers and mothers with normal body weight may be influenced by several factors 
besides diet, such as genetic differences in desaturases. 
The metabolism of essential FA to LCPUFA is genetically regulated by the FA desa-
turase 193, the expression of which was not analyzed in our study. Smoking is known 
to influence DHA status 194, and maternal smoking might explain 50 % of the decrea-
sed plasma n-3 FA concentrations in the obese mothers’ neonates found in our study, 
but the difference remained significant after stratifying for smoking. A recent study 
showed that EPA could be increased by increased vegetable intake 195. EPA, but not 
DHA, differed between the obese groups in our study, suggesting that there was no real 
difference between the groups regarding the intake of fish and seafood, supporting the 
theory that the higher EPA concentration might be attributable to vegetable intake. Hig-
her concentrations of n-6 FA, in relation to the n-3 LCPUFA, are seen in Western food, 
especially in processed and fast food such as fish sticks 196, and have been associated 
with future obesity in animal offspring 197. One observation in our study was that the 
LA level was high both in the control and intervention groups, reflecting the general 
recommendations to increase vegetable oil and reduce saturated fat intake. The GWG 
was significantly lower in the intervention group than in the obese group. To what 
extent this was due to increased PA or to the dietary intervention cannot be evaluated 
using this study design and it is unknown how PA affects the FA pattern in breast milk. 
In animal studies, high n-3 FA concentrations during pregnancy were associated with 
smaller and fewer adipocytes in the offspring 198. In this small study, we found no influ-
ence on anthropometry or ponderal index at birth or at one year of age in the babies, but 
the study might have been too small or the ponderal index might have been too crude a 
parameter to rule out a difference. The infants in our intervention group had the highest 
LA concentration in plasma on the third day of life, which could be explained by intake 
of LA-rich food around and after delivery. The obese and normal-weight mothers were 
included at random and not randomized and the intervention group was voluntarily in-
cluded, which may have created a selection bias. The mothers were instructed to collect 
their milk samples directly after breastfeeding but since the FA content differs in breast 
milk during the day, and especially within feeding portions this might have affected 
results. It has not been shown that the baby’s gender affects breast milk or plasma FA 
but it is a possibility. We therefore chose a control with the same gender as the case. 
Higher maternal n-3 polyunsaturated FA (PUFA) intake, higher cord plasma n-3 PUFA 
and a lower n-6/n-3 ratio were associated with a decreased rate of obesity in children at 
three years of age 128. If our results are confirmed, they may also contribute to the un-
derstanding of why children of obese mothers have an increased risk of future obesity.
A healthy lifestyle is important for both the mother and her baby during pregnancy and 
breastfeeding and lifestyle interventions may be as important for maternal as for infant 
health, but long-term follow up is necessary in order to evaluate the effects of such 
interventions.
6. 3. Paper III
In this nationwide study, we found that maternal overweight and obesity decreased 
the risk of anal sphincter lacerations in a near-linear fashion. The inverse correlation 
between increasing BMI and the occurrence of anal sphincter lacerations was clear, but 
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the highly significant p-values were attributed to the very large sample size rather than 
to major effects. Because obese women are at increased risk of  cesarean section as a 
result of obstetric complications, we restricted the study population to women with va-
ginal deliveries. The rates of grade III and IV perineal tears decreased with increasing 
BMI, whereas the opposite was true for grade I and II perineal tears. Previous studies 
have shown conflicting results regarding the influence of obesity on perineal lacera-
tions 199-201. We can only speculate as to the reasons for the seemingly protective effect 
of overweight and obesity on the pelvic floor found in this study. Estrogen and oxyto-
cin receptor efficacy in uterine smooth muscle are modulated by cholesterol which, 
in turn, is elevated in the serum and myometrial membranes of obese women 202. This 
may provide a certain degree of protection against oxytocin overstimulation during the 
second stage of labor, thereby decreasing the risk of excessive contractions and sub-
sequent pelvic floor injury. On a similar note, uterine smooth muscle has been shown 
to contract with less force and frequency and to have less Ca2+ flux in obese than in 
normal-weight women 203. Choo et al reported that abdominal skin in morbidly obese 
women undergoing bariatric surgery exhibited greater tensile strength than skin from 
normal-weight patients undergoing cosmetic procedures 204. It is uncertain whether 
these results can be generalized to pelvic floor connective tissue, but they do provide 
a possible mechanism through which obese women may contract less obstetric anal 
sphincter lacerations. The issue of whether maternal birth position influences the risk 
of anal sphincter laceration remains controversial. Gottvall et al showed that women 
giving birth in the lithotomy or squatting position had a higher incidence of grade III 
and IV perineal tears 205. Overweight and obese women may not be prone to assuming 
these positions because it may restrict their lung function 206. 
The strengths of our study include the large study population, the nationwide design, 
the homogeneous classification of important confounders and outcome measures and 
the categorization of obesity according to international standards. The use of high-qu-
ality health care registers, based on standardized records throughout the country and 
non-selective registration, are major advantages with regard to data ascertainment. At 
the same time, we recognize that the classification of our primary outcome measure 
(prevalence of anal sphincter lacerations) has some limitations. First, the diagnosis was 
not verified by ultrasound, but relied exclusively on subjective clinical assessments. 
However, anorectal ultrasound is also an investigator-dependent method and diagnosis 
may thus vary between investigators with this method as well. Midwives’ routines for 
examining perineal lacerations after delivery differ. In some departments, they routine-
ly perform a rectal examination immediately after birth, whereas this is not the case in 
others. It is unknown whether sphincter lacerations are misclassified in obese women 
to a higher extent, which might affect results. There may also be regional variations 
with regard to vigilance and willingness to report the occurrence of anal sphincter 
lacerations. Consequently, local, regional and sometimes national under-reporting of 
anal sphincter injuries at delivery may be a limitation of register-based studies. Obese 
women are at increased risk of both anal and urinary incontinence 207,208. If the diagno-
sis of grade III - IV perineal lacerations is considered a proxy for pelvic floor trauma, 
it may be postulated that the increased risk of stress urinary incontinence among obese 
and overweight women should be attributed to increased intra-abdominal pressure, re-
sulting in urethral sphincter incompetence, rather than to pelvic floor injury at delivery. 
It is widely assumed that the first childbirth is associated with the greatest risk of pelvic 
floor trauma and that subsequent deliveries have less impact on obstetric pelvic floor 
sequelae 209. This study was limited to primiparas and we can thus not say whether this 
is the case for overweight/obese women, although it is biologically plausible. In con-
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currence with most previous studies, we found that instrumental delivery (vacuum ex-
traction) significantly increased the risk of anal sphincter lacerations 210. The near-thre-
efold increase in risk attributed to instrumental delivery also remained after adjustment 
in multivariate analysis, exhibiting the strongest association with anal sphincter lacera-
tions. Other factors, such as maternal age, diabetes and head circumference, showed no 
or limited associations with the occurrence of anal sphincter lacerations. Our analysis 
did not include information on fundal pressure during the final stages of labor (not 
registered) or episiotomy (not validated). Thus, we cannot account for the effects of 
these obstetric interventions which may, to some extent, have influenced our results. 
Macrosomia (birth weight > 4.5 kg) and increasing birth weight increased the risk of 
anal sphincter lacerations by the same magnitude as instrumental delivery, but did not 
change the overall inverse correlation between BMI and the risk of anal sphincter lace-
rations in the adjusted analysis. Our data concur with previous studies, suggesting that 
increasing birth weight and macrosomia enhance the risk of anal sphincter lacerations 
at delivery 210 ,211, although the longer-term association with anal incontinence remains 
the subject of debate. In summary, this large-scale, nationwide study provides robust 
epidemiological evidence that overweight and obesity decrease the risk of obstetric 
anal sphincter lacerations among primiparas. As a consequence, decisions to perform 
elective  cesarean section in obese women should not be based on concerns for increa-
sed risks of grade III or IV perineal lacerations.
6. 4. Paper IV
Obese women generally consume significantly more health care resources during preg-
nancy up until seven days prior to delivery, compared to normal-weight women. Obese 
women are more often admitted for in-patient care, had longer antenatal hospital stays 
and were more often sick-listed by an obstetrician during their pregnancy, compared to 
normal-weight women. 
Numerous studies have documented the increased risks of adverse outcomes associated 
with obesity during pregnancy and delivery but few studies have reported on obesi-
ty-related consumption of health care services during pregnancy. Two studies from 
France and one from the US showed that the average costs of in-patient care were sig-
nificantly higher for overweight and obese women than for normal- weight women. In 
these studies, most of the increased hospital stay durations among obese women were 
related to increased rates of  cesarean delivery and obesity-related high-risk conditions 
at delivery 212-214. This study, however, shows that obesity increases the rate of hospi-
tal admissions and length of stay prior to delivery as well. Obesity is thus a source of 
economic burden for antenatal health care, not only in an outpatient setting, but also 
involving relatively costly hospital care.    
In Sweden, the social welfare system allows for sick-listing by a physician in cases of 
transient or permanent disability caused by disease, in which case the cost and loss of 
income are partly reimbursed by the state. In this study, one in three obese women was 
reported to have been sick-listed during pregnancy. This sick-listing increased in a ne-
ar-linear fashion with increasing BMI. Sick-listing may have been due to either soma-
tic or mental illness. Given that approximately one in ten pregnant women in Sweden 
are obese, it is safe to say that society’s health care costs for sick-listing attributed to 
obesity are considerable. Since we had no access to detailed information on sick-listing 
diagnoses or duration, the extent of inability to work and the association with obesity 
requires further studies.  
In this study, obese women visited both midwives and doctors at Maternal Health Care 
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Centers significantly more often than normal-weight women. Given that obesity during 
pregnancy is considered a risk, it is somewhat surprising that the difference was not 
even greater. Part of the increased number of visits to health care providers was related 
to somatic pregnancy complications. Obese women had higher rates of hypertension, 
preeclampsia and diabetes. Whether the greater number of visits to Maternal Health 
Care Centers was related to worry and anxiety among obese pregnant women is a mat-
ter of speculation, albeit indirectly supported by the significantly higher referral rate to 
Aurora units among obese women, compared to normal-weight women. Obese women 
are known to experience feelings of anxiety and worry related to the upcoming birth to 
a higher degree than normal-weight women 215. 
It is well-known that obesity is associated with an increased risk of pregnancy com-
plications, including hypertension, preeclampsia, diabetes and LGA babies32. Our stu-
dy convincingly shows that cardiovascular and metabolic pregnancy complications 
not only affect antenatal surveillance resources but also have direct implications for 
in-hospital care consumption during pregnancy. While this finding is of importance 
for allocating health care resources, it also highlights the need for prevention. It has 
been shown that that rates of preeclampsia, cesarean section, instrumental delivery and 
LGA can be reduced in obese women with low GWG, compared to those with high 
GWG 216. It has also been demonstrated that GWG among obese women can safely 
be restricted through soft interventional programs including dietary advice and PA, 
as well as supportive counseling and monitoring by dedicated staff 173,217. Moreover, 
Stafne et al showed that the proportion of women sick-listed due to lumbar-pelvic 
pain was lower in a group of women undertaking aerobic and strengthening exercises 
during pregnancy, compared to women given standard antenatal care 218. Another study 
showed that water aerobics prevented low back or pelvic pain and reduced sick-listing 
duration during pregnancy169. Back pain is more common in obese women than in nor-
mal-weight women and increases with age 219, which may yield additional health care 
benefits from an interventional program for the former group. 
Obesity is a well-established risk factor for premature childbirth and the risk increases 
with increasing BMI. Premature birth has major impact on the demand for specialized 
care and hospital resources for both infant and mother. In our study we found that, 
regardless of smoking, obese women were less likely to be hospitalized for imminent 
premature labor, i.e. childbirth before gestational week 37. There may be several rea-
sons for this, including misdiagnosis of premature contractions which might be more 
difficult to diagnose correctly in obese women. It might also be that obese women are 
less inclined to seek delivery care or that they may perceive contractions differently 
than do normal-weight women.    
Smoking before pregnancy, at the first antenatal visit, and three months into pregnancy 
increased significantly with increasing BMI. Among the morbidly obese, 10 % admit-
ted that they were still smoking in gestational week 30-32, despite mandatory coun-
seling and information by midwives at Maternal Health Care Centers . Smoking does 
not appear to confound the association between the increased prevalence of hyperten-
sion, preeclampsia and gestational diabetes with increasing BMI. Because antenatal 
health care is free of charge for all Swedish residents, it is unlikely that a socio-eco-
nomic selection bias would result in underestimation of the effects of smoking. Many 
studies have showed that smoking during pregnancy reduces the risk of preeclampsia 
and gestational hypertension by up to 50 % 220. However, the prevalence estimates of 
these cardiovascular diseases were practically unaffected by the exclusion of smoking 
women in a separate analysis. There might have been several reasons for this. First, 
it is possible that the mechanisms underlying the protective effects of smoking on the 
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risk of preeclampsia among obese women differs from the corresponding mechanisms 
among normal-weight women. Second, the number of smokers with preeclampsia and 
hypertension was low and exclusion of these women did thus not have a significant 
impact on the occurrence of disease. In this case, an even larger study population might 
have yielded a different result. Third, an unknown confounder may have interfered 
with the analysis. Further studies are necessary to determine how smoking affects the 
occurrence of cardiovascular disease during pregnancy among obese women. 
The strengths of our study include a very large study population, the use of nationally 
uniform outcome measures and the availability of high-quality health care registers. 
Although much attention has been devoted to morbidity and complications surroun-
ding delivery, this is one of the few studies focusing on antenatal health care consump-
tion among obese women. The unique national registration number assigned to all 
Swedish residents, at birth or immigration, allowed for unambiguous record linkage 
across the registers, as well as minimizing selection and ascertainment bias. Among 
the limitations of our study, it should be noted that the Maternal Health Care Register 
does not have nationwide coverage and regional variations in demographics may have 
influenced the available data and thereby results. Nonetheless, the register includes 
both urban and rural populations and has a geographical spread throughout the country, 
the population of which is relatively homogeneous. Most of the data regarding preg-
nancy morbidity was derived from the validated IPR. Although efforts are underway, 
the Maternal Health Care Register has not yet been formally validated and data quality 
can therefore not be ascertained. 
This study showed that increasing BMI also increased the consumption of health care 
resources during the antenatal period. Given the major health economic and medical 
consequences of pregnancy in overweight and obese women, all attempts should be 
made to prevent obesity in women of childbearing age and to encourage weight loss 
before pregnancy. In women entering pregnancy with manifest obesity, interventional 
programs may reduce both health care consumption and morbidity. 
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7. Conclusions
7. 1. Study I 
This pilot study showed that an early intervention program, including general dietary 
advice and increased physical activity, may be successful in helping obese women 
control gestational weight gain without adverse perinatal outcomes.
7. 2. Study II
In this comparative study, fatty acids in breast milk of obese mothers and plasma phosp-
holipids from their neonates differed significantly from the corresponding fatty acids 
in normal-weight mothers and their neonates. Obese pregnant women and their neona-
tes had lower omega-3 fatty acids and higher omega-6/omega-3 fatty acid ratios than 
normal-weight mothers and their infants. A general weight control program seemed to 
improve the fatty acid pattern. The results suggest the importance of health-promoting 
care for obese pregnant women, which may also influence the early fatty acid pattern 
in their infants.
7. 3. Study III
This large-scale nationwide study provides robust epidemiological evidence that over-
weight and obesity decrease the risk of obstetric anal sphincter lacerations among pri-
miparas.
7. 4. Study IV
This large population-based cohort study showed that obese women generally consume 
significantly more health care resources during pregnancy, compared to normal-weight 
women. Obese women were more often admitted for in-patient care, had longer ante-
natal hospital stays, and were more often sick-listed during pregnancy, compared to 
normal-weight women. There was a small but significant increase in the number of vi-
sits to both obstetrician and midwife with increasing BMI category. Given that obesity 
during pregnancy is considered a risk, it is somewhat surprising that the difference was 
not even greater.
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8. Svensk sammanfattning (Swedish summary)
Fetma ökar i hela Västvärlden. Enligt WHO (World Health Organization) är mer än 
300 miljoner människor i världen feta d.v.s. har body mass index över 30 kg / m2. 2011 
var 50 % av alla män och 40 % av alla kvinnor överviktiga eller feta i Sverige (feta män 
11.8 % resp. feta kvinnor 10.5 %). Samma år hade 12.6 % av alla gravida kvinnor ett 
BMI som översteg 30. Övervikt och fetma under graviditet ökar risken för ett flertal 
komplikationer, som ökad risk för missfall, för tidig födsel, havandeskaps-förgiftning, 
graviditetsdiabetes, blodproppar och kejsarsnitt. Vid förlossningen ökar risken för sto-
ra blödningar och risk för allvarliga komplikationer ökar med BMI i samband med 
kejsarsnitt. Barnen till dessa mödrar har ökad risk för missbildningar, att födas tunga 
för tiden, att dö innan förlossningen och har högre risk att få syrebrist i samband med 
förlossningen. Studier visar att stor viktökning under graviditeten ökar risken att föda 
ett barn som är tung för tiden och att kostråd och ökad fysisk aktivitet under graviditet 
för feta gravida minskar risken för bland annat havandeskapsförgiftning. Förlossning-
ens första del går långsammare hos kvinnor med högt BMI men den senare, aktiva 
delen av förlossningen påverkas inte av kvinnans BMI. 
Fetmaincidensen ökar också bland barn. Orsaker kan vara minskad fysisk aktivitet och 
ökad intag av snabbmat med högt energiinnehåll. Andra riskfaktorer är att födas av 
överviktiga föräldrar, föräldrar med låg inkomst, ha en mor som röker, kort amnings-
period och snabb viktökning de första 5 månaderna av livet. 
Vad vi äter under graviditet och amningsperioden har stor betydelse för det växande 
barnet. Under andra världskriget utsattes den av Tyskland ockuperade delen av Hol-
land för svår svält. Studier från detta område har visat att kvinnor som utsattes för svält 
i tidig graviditet fick barn som hade ökad risk för fetma som vuxna, medan de barn 
som utsattes för svält under fosterperiodens senare del, hade minskad risk att utveckla 
fetma som vuxna. Många fler studier har efter detta visat att undermålig näring under 
fosterlivet kan påverka både det växande barnet men också kan ha effekt på kommande 
generationer. Detta sammanhang beskrevs först av David Barker 1986 och kallades 
”the Developmental Origins of Health and Disease Hypothesis” eller Barkerhypote-
sen. Gener har förmåga att uttryckas på olika sätt. Varför förändringen sker, beror bland 
annat på omgivningens påverkan, t.ex. beroende på hur mycket och vad vi äter. Detta 
brukar också kallas epigenetik och syftar på vad som sker med uttrycket av DNA utan-
för själva DNA sekvensen i våra gener. 
Omega-3 fettsyran alfalinolensyra (ALA) och Omega-6 linolensyra (LA) är fleromät-
tade fettsyror. De är essentiella fettsyror d.v.s. vi är beroende av dessa i kosten, då vi 
inte kan producera dem själva i kroppen. Dessa fetter är mycket viktiga för bl.a. hjär-
nans utveckling och fostret är därför beroende av moderns intag av ALA och LA under 
fosterlivet och amningsperioden. Vi äter allt mer omega-6 fetter i kosten och mindre 
omega-3, vilket är ett problem då dessa fettsyror konkurrerar om samma enzym i krop-
pen. Ett för högt intag av omega-6 fettsyror kan därför ha en negativ påverkan hur vi 
tillgodogör oss omega-3 fettsyror. Studier har visat risk för både försämrad neurologisk 
utveckling och ökad risk för fetma hos barn som under fosterlivet och amning fått hög 
andel omega-6 och låg andel omega-3 fettsyror. 
48
I denna avhandling ingår fyra olika studier:
I. Ett pilotprojekt med 25 gravida kvinnor med BMI > 30 som ingått i en inter-
ventionsstudie med extra besök hos barnmorskan, läkare, dietist och extra 
motion, vattengymnastik 1gg / vecka samt egen träning minst 30 minuter/
dag under hela graviditeten. Resultaten visade att 56 % av kvinnorna gick 
upp ≤ 6 kg vilket var målet för projektet. 3 kvinnor fick en blodtrycksförhöj-
ning under graviditeten, tre kvinnor förlöstes med kejsarsnitt. Alla barn var 
friska och hade normal födelsevikt. 
II. En observationsstudie där fettsyror i bröstmjölk och i blodprov från barnen 
jämfördes mellan 41 normalviktiga, 41 feta och 29 feta kvinnor från inter-
ventionsstudien. Resultaten visade att omega-3 fettsyror var lägst och kvo-
ten omega-6 / omega - 3 fettsyror högst i bröstmjölk och i blodprov hos de 
feta kvinnorna och deras barn. Fettsyrorna i bröstmjölk och blodprov från 
kvinnor respektive barn med högt BMI som ingått i interventionsstudien var 
mer lika de normalviktiga kvinnornas fettsyror.
III. En stor nationell studie från Medicinska födelseregistret, med 210,678 först-
föderskor, där risk för skador i ändtarmsmuskeln jämfördes mellan kvinnor 
i olika BMI klasser. Resultatet visade att risken för skador i ändtarmsmus-
kel minskade ju högre BMI kvinnan hade. 
IV. En stor nationell från Mödrahälsovårdsregistret, Medicinska födelseregistret 
och Slutenvårdsregistret med 108,103 förstföderskor där sjukvårdskonsum-
tion och sjukskrivning jämfördes mellan kvinnor i olika BMI klasser. Resul-
tatet visade att kvinnor var mer sjukskrivna ju högre BMI de hade och att de 
hade mer besök hos barnmorska och läkare på mödravårdscentralen, fler 
besök för samtal om förlossningsrädsla och var oftare inlagda på sjukhus 
under graviditeten. 
 
Sammanfattning: Det är känt att med ökande BMI ökar risken för en rad komplikatio-
ner under graviditeten. En del av dessa komplikationer går att minska om viktuppgång-
en inte blir för stor. Andra komplikationer kan upptäckas tidigt, eller undvikas, med 
bättre övervakning under graviditet och förlossning. Förlossningsförloppet är lite olika 
beroende på kvinnans BMI men risken för allvarliga skador i underlivet är mindre hos 
kvinnor med högt BMI och information om detta kan hjälpa feta gravida att våga föda 
vaginalt. Modern och hennes barn påverkas av kost och motion under graviditet och 
amning och det är därför viktigt att i tidig graviditet hjälpa kvinnor att förbättra sina 
kost och motionsvanor. Vår interventionsstudie visar hur man skulle kunna hjälpa feta 
kvinnor under graviditeten, men större randomiserade studier behövs, innan man kan 
införa detta fullt ut i klinisk praxis. 
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